Active remodeling of the chromatin landscape directs extravillous trophoblast cell lineage development

Kaela M. Varberg[1,2,*,†], Esteban M. Dominguez[1,2,†], Boryana Koseva[3], Joseph M. Varberg[4], Ross P. McNally[1,2,¥], Ayelen Moreno-Irusta[1,2], Emily R. Wesley[3], Khursheed Iqbal[1,2], Warren A. Cheung[3], Carl Schwendinger-Schreck[3], Craig Smail[3], Hiroaki Okae[5], Takahiro Arima[5], Michael Lydic[6], Kristin Holoch[6], Courtney Marsh[1,6], Michael J. Soares[1,2,6,7,*], and Elin Grundberg[1,2,3,*]

[1]Institute for Reproductive and Developmental Sciences, University of Kansas Medical Center, Kansas City, Kansas 66160

[2]Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160

[3]Genomic Medicine Center, Children's Mercy Research Institute, Children's Mercy Kansas City, Kansas City, MO 64108

[4]Stowers Institute for Medical Research, Kansas City, MO 64110

[5]Department of Informative Genetics, Environment and Genome Research Center, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan

[6]Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, Kansas 66160

[7]Center for Perinatal Research, Children's Mercy Research Institute, Children's Mercy, Kansas City, MO 64108

[†]These authors contributed equally

[¥]Present address: Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611

*Correspondence to kvarberg@kumc.edu; msoares@kumc.edu; egrundberg@cmh.edu

ABSTRACT

The extravillous trophoblast (**EVT**) cell lineage is a key feature of placentation and successful

pregnancy. Knowledge of transcriptional regulation driving EVT cell development is limited.

Here, we mapped the transcriptome and epigenome landscape as well as chromatin

interactions of human trophoblast stem (**TS**) cells and their transition into EVT cells. Integration

of chromatin accessibility, long-range chromatin interactions, transcriptomic, and transcription

factor (**TF**) binding motif enrichment enabled identification of TFs and regulatory mechanisms

associated with EVT cell development. Functional roles for *TFAP2C*, *SNAI1,* and *EPAS1* in the

regulation of EVT cell development were elucidated. *EPAS1* was identified as an upstream

regulator of key EVT cell TFs, including *ASCL2* and *SNAI1* and together with its target genes,

was linked to pregnancy loss and birth weight. Collectively, we have revealed activation of a

dynamic regulatory network that provides a framework for understanding EVT cell specification

in trophoblast cell lineage development and human placentation.

INTRODUCTION

Pregnancy disorders such as recurrent pregnancy loss (**RPL**), preeclampsia, intrauterine growth restriction, and preterm birth can be the result of inadequate delivery of maternal blood to the growing fetus, a consequence of insufficient spiral artery remodeling[1]. Spiral artery remodeling is largely dependent on the function of a specialized population of trophoblast cells termed extravillous trophoblast (**EVT**) cells[2]. EVT cells are terminally differentiated trophoblast cells that invade into and restructure the uterine compartment, including transforming tightly coiled spiral arterioles into large, distended vessels capable of increasing blood delivery to the developing fetus[3]. EVT cells take two routes of invasion into the uterine parenchyma: interstitial and endovascular. Interstitial EVT cells migrate within the stromal compartment between the vasculature, whereas endovascular EVT cells invade into vessels where they replace endothelial cells and adopt a pseudo-endothelial phenotype[2,4]. In addition to increasing blood volume, EVT cell-remodeled spiral arteries decrease blood flow velocity, and consequently shear stress damage to uterine vessels[5]. The contributions of EVT cells to uterine transformation and successful pregnancy imparts importance to understanding the acquisition of an EVT cell fate. To date there is a limited knowledge of regulatory networks controlling EVT cell differentiation.

Comparisons of rodent embryonic stem (**ES**) and trophoblast stem (**TS**) cells using an assortment of approaches to characterize the transcriptome and epigenome have helped define the regulatory landscape critical for establishment of the trophoblast cell lineage[6–14]. These insights helped identify core transcription factors (**TFs**) essential for reprogramming mouse fibroblasts into TS cells[15,16]. Advancements have also been achieved in understanding higher-order regulatory networks controlling aspects of rodent trophoblast cell differentiation, including the identification of putative TF-gene regulated networks[8,12,17–20]. The execution of similar experimentation regarding human trophoblast cell development would be informative.

A range of *in vitro* model systems for investigating human trophoblast cell lineage

development have been proffered but all have fallen short in adequately replicating

establishment of the EVT cell lineage[21]. A fundamental problem has been in distinguishing

features intrinsic to EVT cells from those associated with the immortalization or transformation

processes used to establish the *in vitro* models. In 2018, culture conditions needed to maintain

human TS cell renewal and to differentiate TS cells into EVT cells were established[22]. The

human TS cell model is robust and has been utilized to provide new insights into the

development of the human trophoblast cell lineage[20,23–26]. However, systematic profiling of open

chromatin, chromatin contacts and associated transcriptional signatures in human TS cells and

differentiated EVT cells have not been performed to date.

To this end, we applied multiple functional genomics approaches using next-generation

sequencing (**NGS**) and contrasted the regulatory landscape of trophoblast cells in the stem

state and following differentiation into EVT cells using human TS cells as a model[22]. The

experimentation included systematic assessments of the transcriptome by RNA-sequencing

(**RNA-Seq**), chromatin accessibility using Assay for Transposase-Accessible Chromatin-

sequencing (**ATAC-Seq**), and high throughput chromosome conformation capture (**Hi-C**),

respectively. We integrated these analyses to identify higher-order regulation of human EVT cell

differentiation, which was validated by histone modifications (chromatin immunoprecipitation-

sequencing, **ChIP-Seq**) in the TS cell model and single-cell RNA sequencing (**scRNA-Seq**) of

first trimester human placenta samples. Collectively, the analyses provide a rich resource for

dissecting functional genomics of placental-related diseases of pregnancy. Using this resource,

we identified candidate TFs and demonstrated their critical role in EVT cell lineage development

with links to pregnancy complications.

RESULTS

An atlas of regulatory DNA and transcriptional profiles of human TS and EVT cells

We developed a comprehensive functional genomics resource of trophoblast cell development by utilizing human TS cells maintained in the stem state and following differentiation to EVT cells[22] (**Fig. 1a**). We first performed a time course analysis monitoring the transition from stem state towards EVT cells at four timepoints [stem state (day 0), day 3, day 6, and day 8]. We noted clear differences in global gene expression at day 0, 3, and 6 (**Fig. 1b**). Expression profiles were more similar at days 6 and 8 of EVT cell differentiation. The upregulated genes included expression of commonly used EVT lineage markers[20] (**Fig. 1c, Supplementary Fig. 1a**), as well as induction of *HLA-G* (**Fig. 1d**, **Supplementary Fig. 1b, Supplementary Fig. 2**). Similarly, morphological changes as TS cells transition from discrete colonies into individual, elongated EVT cells were verified and most pronounced at day 8 (**Fig. 1e, Supplementary Fig. 1b**). Based on these results, we focused on the stem state and EVT cells following eight days of differentiation (day 8) and generated RNA-Seq and ATAC-Seq profiles for multiple replicates of two TS cell lines: CT27 (46, XX) and CT29 (46 XY) (**Supplementary Table 1**). Overall, we identified 2938 transcripts that were significantly upregulated (log2 fold change >1, adjusted p<0.05) in EVT cells compared to trophoblast cells in the stem state and 3055 transcripts that were significantly downregulated (**Supplementary Table 2, Fig. 1f**). The robustness and consistency of the TS cell model was confirmed in multiple ways. First, TS cell transcriptomes obtained from independent experiments were contrasted to previously reported transcriptomes for the same TS cell line[22] (Pearson correlation 0.64) (**Supplementary Fig. 3a-b**). Second, transcriptomes and active regulatory regions as assessed by RNA-Seq and ATAC-Seq, from CT27 and CT29 TS cell lines were compared across cell states showing high concordance (**Supplementary Fig. 3c-e**). Finally, we used publicly available single-cell gene expression data from EVT cells (n=693 cells) isolated from normal first trimester placental samples[27,28] and contrasted with expression profiles of a

combined group of other trophoblasts with markers of syncytiotrophoblast (**SCT**) and villous

cytotrophoblast (**VCT**) (n=7,834 cells) (**Fig. 2a**). We found high concordance of differentially

expressed genes in the TS cell culture model with the *in vivo* data (**Fig. 2b**; **Supplementary**

Fig. 4). Similarly, gene set enrichment analysis (**GSEA**) using the top 250 *in vivo* markers of the

SCT/VCT and EVT lineages, respectively, from the single-cell gene expression data revealed

statistically significant enrichment of expression patterns in the *in vitro* TS cell model

corresponding to false discovery (FDR) q value of 0.2% for both EVT and Stem state cells

GSEA, respectively (**Fig. 2c-e**).

Thus, the *in vitro* human TS cell culture model can be successfully leveraged to gain

insight into human EVT cell lineage development. We use CT27 as our reference cell line for all

subsequent global and targeted analysis with orthogonal validation in CT29 accordingly.

EVT cell differentiation drives global changes in chromatin accessibility

Although reference maps of regulatory DNA have been generated across hundreds of

human cell and tissue types and states, trophoblast cell lineage representation within these

reference maps is sparse and is restricted to either bulk placental samples or embryonic stem

cell-derived trophoblast cells without distinction of specific cell lineages or developmental

states[29,30]. Using ATAC-Seq at high sequencing depth across multiple replicates, we have

expanded these resources and provided maps of regulatory regions in the trophoblast cell stem

state and following differentiation to EVT cells. We analyzed these regulatory regions in multiple

ways. First, we called ATAC-Seq peaks, which are markers of open chromatin, jointly across

replicates and identified, at 1% false discovery rate (**FDR**), 165,094 (**Supplementary Table 3a**)

and 142,520 (**Supplementary Table 3b**) open chromatin regions in stem and EVT cell

developmental states, respectively. We then conservatively assessed shared accessible regions

by overlapping specific coordinates and included a minimum one base pair (**bp**) overlap. This

conservative assessment identified 63% versus 73% of the accessible regions as shared and

37% versus 27% of the regions as unique to the stem state versus EVT cell state, respectively.

The accessible regions that were shared between stem and EVT cells were distributed similarly

across the genome compared to other reported human tissues and cells, with the majority

mapping to intronic (44%) or intergenic (32%) regions and a smaller subset mapping to

promoter regions (14%) (**Fig. 3a**). However, when contrasting stem versus EVT cell-specific

regions, we noted that the genomic distribution of EVT cell-specific regions was shifted, with a

larger proportion mapping to intergenic regions (40% versus 34%) and a smaller proportion

mapping to promoter regions (4% versus 8%). This shift points toward increased enhancer-

driven gene regulation in EVT versus stem state cells (**Fig. 3a**). These observations are

reinforced by contrasting sequence coverage in ATAC-Seq, where the coverage is enriched

near transcription start sites (**TSS**) for shared accessible regions, but not for EVT cell-specific

regions (**Fig. 3b**).

We expanded our annotation of stem and EVT cell open chromatin regions to include

the atlas of regulatory DNA that was created from 16 different human tissue types or states[29].

This extensive atlas was used as a comparative reference standard. We found that as many as

97% of shared stem and EVT cell regions were previously annotated to regulatory DNA,

including 11% that were specific to placental or embryonic/primitive origin. Interestingly, within

accessible chromatin regions that were unique to EVT cells, 17% were placental-or

embryonic/primitive specific (**Supplementary Table 3a-b**).

To characterize the regulatory regions identified by ATAC-Seq in further detail we

integrated ChIP-Seq based histone modification data for stem state and EVT cells and noted

enrichment of ATAC-Seq coverage near H3K27ac and H3K4me3 peaks for both stem state and

EVT cells, respectively (**Fig. 3c**)

To identify consensus regulatory regions that display different chromatin accessibility as

an indication of different transcription factor (**TF**) binding patterns in stem versus EVT cells, we

next applied an alternative approach that utilized individual ATAC-Seq replicates in stem state

cells (n=7) and EVT cells (n=7). The consensus regulatory regions we considered in this

analysis were 1) covered by at least 10 counts per million reads, 2) fixed windows of 400 bp in

size, 3) mapped to an ATAC-Seq peak, and 4) appeared in more than two of the samples. For

the 41,465 identified consensus regions, 40,508 and 38,785 mapped to ATAC-Seq peaks in

stem state and EVT cells, respectively, and the individual replicates clustered together with the

largest amount of variability attributed to differences between the two cell groups

(**Supplementary Fig. 5a-b**). Based on estimated binding affinity measured by differences in

ATAC-Seq read densities, we identified a total of 23,504 and 9,334 regions that were

differentially enriched (5% FDR) and considered more accessible in the stem state and EVT cell

state, respectively. We annotated these regulatory regions using the orthogonal ChIP-Seq

based histone modification data for active enhancers (H3K27ac) and promoters (H3K4me3)

(**Fig. 3c**; **Supplementary Table 4a-b**). In all, we found 78% versus 76% of the differentially

enriched ATAC-Seq regions to map to an active enhancer (H3K27ac) or promoter (H3K4me3)

in stem state versus EVT cells, respectively. However, when considering the epigenetic marks

separately we noted a clear difference across the two cell states. Specifically, while 36% of

differentially enriched ATAC-Seq regions in the stem state overlapped an active enhancer (**Fig.**

3c) as many as 65% of the differentially enriched ATAC-Seq regions in the EVT cell state

overlapped an active enhancer marked by a H3K27ac peak (**Fig. 3d**). Interestingly, differentially

enriched ATAC-Seq regions in the stem state were an order of magnitude more likely to map to

a putative poised/bivalent promoter (marked by a H3K4me3 peak without an overlapping

H3K27ac peak) than differentially enriched ATAC-Seq regions in the EVT cell state (**Fig. 3c-d**).

Bivalent chromatin are characterized by having both repressing and activating role of gene

expression regulation with important role in cell differentiation[31]. Although we note that the

repressive chromatin mark H3K27me3 is required to fully distinguish a poised/bivalent promoter

we speculate that these enriched promoter regions in the stem state may silence genes that will

activate EVT differentiation as exemplified for *HLA-G* (**Supplementary Fig. 6b and**

Supplementary Fig. 7a). On the other hand, the enrichment of H3K27ac peak among the

differentially enriched ATAC-Seq regions in the EVT cell state further point to significant

increased enhancer-driven gene regulation in EVT versus stem state cells[31].

For the EVT cell differentially accessed regulatory regions, we integrated expression

data measured by RNA-Seq for regions mapping within 10kb of the TSS for a gene (n=1,576

genes) and also found a striking enrichment of EVT cell-upregulated genes mapping near these

EVT cell differentially accessed regulatory regions (log2fold >1; adjusted p<0.05), which

corresponded to 2.6-fold enrichment (Chi^2=615; Fisher p<0.0001) (**Supplementary Table 5**).

We noted that many of these differentially bound active regulatory regions linked to differentially

expressed genes were those known to be implicated in the regulation of intrauterine trophoblast

cell invasion (e.g., *MMP2*, *HLA-G*, and *ASCL2*) (**Supplementary Fig. 6a-c and Supplementary**

Fig. 7a-c).

Long-range chromatin interactions define unique gene regulation machinery in EVT cells

Regulatory DNA that is specific to EVT cells can provide insight into potential

transcriptional regulators of EVT cell differentiation and its associated gene expression profile.

Due to the significant enrichment of EVT cell-specific regulatory regions near genes with EVT

cell-specific expression patterns, we hypothesized that a subset of these regions would map to

super-enhancers. A super-enhancer is operationally defined as a large cluster of transcriptional

enhancers in close proximity that drive expression of a gene(s)[32]. Super-enhancers determine

cell identity and can provide insight regarding key TFs underlying the differentiation process[12,33].

To test this, we used the ATAC-Seq data to identify super-enhancers based on established

algorithms[34]. We identified a total of 1,283 super-enhancers, of which 309 mapped to 611

differentially bound ATAC-Seq peaks (**Supplementary Table 6**).

To identify long-range chromatin interactions involving EVT cell super-enhancers and

regulatory regions identified by ATAC-Seq we performed Hi-C chromatin capture. We obtained

long-range intra-chromosomal contacts after aligning and filtering Hi-C read pairs across all Hi-

C samples and called chromatin loops at 5 kb resolution (**Fig. 4a**). Using this threshold, we

identified 11,999 stem state (**Supplementary Table 7a**) and 14,516 (**Supplementary Table 7b**)

EVT cell chromatin loops with a minimum and median distance between anchors corresponding

to 30 kb and 260-275 kb, respectively (**Fig. 4b**). These observations are consistent with efforts

using other cell models[35,36]. We found that CCCTC-binding factor (**CTCF**) binding motifs were

the most enriched TF binding motifs within the loop anchors (covering 60% of all EVT loop

anchors). This observation confirms previous efforts that indicate the important role of CTCF in

shaping the three-dimensional structure of the genome[37,38], in addition to the function it serves

as a transcriptional repressor and insulator[35]. The validity of the Hi-C chromatin capture was

confirmed in the CT29 donor line showing high concordance for both stem state and EVT cell

chromatin loops, respectively (**Supplementary Fig. 8a)**.

To identify long-range chromatin interactions, or Hi-C loops, that are specific to either

stem state or EVT cells (i.e., differential loops), Hi-C loops from the stem state were integrated

using the same parameters described for EVT cells above (**Fig. 4b-c**). Using previously

established algorithms[39], we identified 99 and 349 loops to be stem- and EVT-cell specific,

respectively (**Supplementary Table 7a-b**). The latter set of differential loops was also shown to

be more robust as shown in orthogonal validation analysis (**Supplementary Fig. 8b**). These

results point to two major properties of cell-specific, Hi-C loops: 1) they are rare due to strongly

conserved chromatin conformation across cell states as shown previously[39] and 2) they are

more common in EVT cells, which could be indicative of increased enhancer-driven gene

regulation (**Fig. 3c**).

To examine the enrichment of chromatin accessibility near the Hi-C loop anchors, we

integrated reads from the ATAC-Seq peaks from the respective cell types. Among all chromatin

loops, we found a clear enrichment of accessible chromatin near the center of the anchors

(**Supplementary Fig. 9a-b**). EVT cell-specific loops displayed a similar pattern; however, there

was no enrichment of accessible chromatin near the center of the anchors for stem state-

specific loops likely due to the low number of loops that were identified (**Supplementary Fig.**

9c-d).

We then focused on the 9,334 EVT cell differentially accessed regulatory regions

(**Supplementary Table 4b**) and showed in aggregate analysis an enrichment of these near the

center of EVT cell loop anchors (**Fig. 4d**). Specifically, we found that 1,239 EVT cell-specific

regions defined by ATAC-Seq overlapped at least one Hi-C loop anchor across a total of 1,518

EVT cell Hi-C loops. Interestingly, of the 1,518 EVT cell chromatin loops identified, 119

contained differentially bound regulatory regions at both anchors and 1,094 had at least one

anchor mapped within 10 kb of a known gene (**Supplementary Table 8a-b**). Among the genes

identified with long-range chromatin interactions of regulatory DNA, several have been

implicated in EVT cell differentiation and function including *ASCL2*, *MMP2*, and *HLA-G*[20,40–42]

(**Supplementary Fig. 10a-b and Supplementary Fig. 11a-b**). Specifically, we identified a

super-enhancer 50 kb upstream of *ASCL2* interacting with its promoter region (**Supplementary**

Fig. 12).

Candidate transcriptional regulators of EVT cell differentiation

To identify transcriptional regulators of EVT cell differentiation we utilized the functional

genomics resource in two ways. First, we used three sets of regulatory regions to perform motif

enrichment of known TF families compared to the genome background. The regulatory regions

included: 1) all differentially enriched EVT cell ATAC-Seq peaks based on estimated TF binding

affinity, 2) differentially enriched EVT cell ATAC-Seq peaks based on estimated TF binding

affinity mapping to an active enhancer and 3) regions in (1) that overlap a super-enhancer (**Fig.**

3f). In all three analyses (**Supplementary Table 9**, we found TEA Domain Transcription Factor

3 (**TEAD3**) and TEA Domain Transcription Factor 1 (**TEAD1**) as the top two ranked TF DNA

binding motifs where both genes were also significantly upregulated in EVT cells (*TEAD3*:

log2fold change=1.6, adjusted p=2E-10; *TEAD1*: log2 fold change=1.3, adjusted p=1E-3;

Supplementary Table 2). In addition to *TEAD1* and *TEAD3*, another 18 TF DNA binding motifs

were identified among the top-ranking TFs across all sets, including Activator Protein 1 (**AP-1**),

Activating Protein 2 (**AP-2**), and GATA TF DNA binding motifs (**Supplementary Table 10**).

TEAD1[43] and *TEAD3* have been linked to trophoblast cell regulation, and a paralog, TEA

Domain Transcription Factor 4 (***TEAD4***), is a known determinant of the stem state[24,44]. *TEAD1*

and *TEAD3*, each displayed unique regulatory landscapes specific to the EVT cell state

(**Supplementary Fig. 13a-b and Supplementary Fig. 14a-b**). *TEAD1 and TEAD3* are more

highly expressed in EVT cells compared to stem state cells, while *TEAD4* is expressed more

highly in the stem state (**Supplementary Fig. 13c**).

AP-2 and GATA TFs are known regulators of trophoblast cell development[45,46]. Indeed,

the most significant motif enrichment among EVT-specific super-enhancers following those for

the TEAD family members was *TFAP2C* (also referred to as AP-2 gamma), which has

previously been implicated in the regulation of early decision making in trophoblast cell lineage

development[46] (**Supplementary Table 9c**). However, the potential contributions of *TFAP2C* to

human TS cell maintenance and terminal trophoblast differentiation remain elusive.

In our second attempt to identify transcriptional regulators of EVT cell differentiation, we

followed-up the top 100 EVT cell-specific chromatin loop-gene associations (**Supplementary**

Table 11) and used the single-cell gene expression data generated from normal first trimester

placental samples for validation (**Fig. 2a**). Approximately 70% of these genes that were found to

possess EVT-cell specific gene regulation and significantly upregulated in TS cell-derived EVT

showed increased expression in the primary EVT cells from the single-cell dataset in

comparison to SCT and VCT cells (**Supplementary Table 11**). We classified these EVT cell-

specific genes based on TF status and revealed five TF genes (*ASCL2*, *DLX6*, *SNAI1*, *MYCN*,

and *EPAS1*) (**Fig. 5**). The regions surrounding each of the five TFs show evidence of EVT cell-

specific regulation (**Fig. 4e**, **Fig. 8e, Fig. 9e, Supplementary Fig. 12, Supplementary Fig. 15a,**

Supplementary Fig. 16a-c, Supplementary Fig. 21a). While *ASCL2* contributes to EVT cell

differentiation[20], the contributions of the other identified TFs in trophoblast cell differentiation are

less understood.

We investigated the role of *TFAP2C*, *SNAI1* and *EPAS1* in the regulation of trophoblast

cell development and EVT differentiation.

Functional investigation of transcriptional regulators of EVT cell lineage development

To evaluate the functions of *TFAP2C* in trophoblast cell development, we first localized

TFAP2C in placental specimens and then performed knockdown experiments in the TS cell

model. Using *in situ* hybridization, we found *TFAP2C* to be expressed within the EVT cell

column of first trimester human placental specimens (**Fig. 6a**). *TFAP2C* co-localized primarily

with *CDH1* (cytotrophoblast marker[47]) and less with *PLAC8* (EVT cell marker)[40,48] transcripts in

EVT cell columns, consistent with its enrichment in the cytotrophoblast/trophoblast progenitor

cell population at the base of the column (**Fig. 6a**). To determine expression profiles in the TS

cell model, we applied RT-qPCR and western blotting to measure *TFAP2C* transcript and

protein levels, respectively. *TFAP2C* transcript is expressed in stem cells and EVT cells (at 8

days) at comparable levels (**Fig. 6b**), with slightly higher expression of *TFAP2C* at the protein

level in the stem state (**Fig. 6c**). However, results from the time-course analysis were more

dynamic and showed a marked upregulation of *TFAP2C* at an early transitional stage in EVT

cell differentiation (day 3) (**Fig. 6d**). These observations suggest that TFAP2C could be involved

in both maintenance of the trophoblast cell stem state and the early stages of EVT cell

differentiation.

The regulatory landscape surrounding the *TFAP2C* locus shows evidence of active

chromatin near TSS of the gene in both stem state and EVT cells. (**Supplementary Fig. 17** and

Supplementary Fig. 18). To elucidate the function of *TFAP2C* in TS cell differentiation we used

a gene silencing approach. *TFAP2C*-specific short hairpin RNA (**shRNA**) stably delivered in the

stem state interfered with *TFAP2C* transcript (**Fig. 6e**) and protein expression (**Fig. 6f**). *TFAP2C*

disruption inhibited TS cell proliferation, altered TS cell morphology (**Fig. 6g**), and adversely

affected cell survival in culture conditions promoting EVT cell differentiation. The effects of

TFAP2C disruption were consistently observed in the CT29 line (**Supplementary Fig. 19**).

Disruption of *TFAP2C* also resulted in broad transcriptomic changes, as identified by RNA-Seq.

Consistent with impaired cell proliferation, several known genes contributing to cell cycle

progression were downregulated, including *AURKA*, *AURKB*, *PLK1*, *MYC*, *EGR1*, *CDK1*,

CCNA2, *CCNB1*, and *MKI67* (**Fig. 6h**). Transcript signatures indicative of the stem state (e.g.,

TEAD4, *PEG3*, and *PEG10*) and EVT cell state (e.g., *IGF2*, *ISM2*, *CDKN1C*, *FOXO4*, *GCM1*,

ASCL2, *SNAI1*, *FSTL3*, *PLAC8*, and *NOTUM*) were also inhibited (**Fig. 6h**). Notable

upregulated genes following *TFAP2C* disruption included *CNN1* and *LAMB3*, which are

associated with the stem state, as well as *MMP2*, *MCAM*, and *SPARC*, which are linked to the

EVT cell state. Ingenuity pathway analysis of the top 500 differentially regulated genes following

TFAP2C disruption highlighted kinetochore metaphase signaling, cell cycle control of

chromosomal replication, as well as cyclins and cell cycle regulation as the top functional

pathways (**Supplementary Fig. 20a**). To assess whether *TFAP2C* is a direct regulator of the

differentially expressed genes identified upon silencing, we performed ChIP-Seq in the stem

state. While we noted an overall overrepresentation (Chi^2=90; Fisher p<0.0001) of TF peaks

close to (within 2kb) downregulated genes (log2fold <-1; adjusted p<0.05) (**Fig. 6h**) the same

pattern was not seen for genes upregulated genes (log2fold >1; adjusted p<0.05,

Supplementary Fig. 20b). Overall, we conclude that *TFAP2C* contributes to cell cycle

regulation mainly as a transcriptional activator and is critical for maintenance of TS cells in a

stem state and early EVT cell lineage development.

To evaluate the functions and potential contributions of *SNAI1* and *EPAS1* to EVT cell

development, we again localized each target in placental specimens by *in situ* hybridization and

performed loss-of-function experiments using the TS cell model in CT27 cells (**Figs. 6-8**) and

CT29 cells (**Supplementary Figs. 22-23**). First, we examined the spatial distribution of each TF

in first trimester human placental tissue and showed that both TFs were more abundant in distal

regions of the EVT column and co-localized with *PLAC8*, a marker of differentiated EVT

cells[40,48] (**Fig. 7a**). *SNAI1* and *EPAS1* (also called HIF2A) were significantly upregulated in EVT

cells compared to stem state cells at the transcript (**Fig. 7b-c**) and protein levels (**Fig. 7d**).

Taken together, both TFs are expressed in EVT cells *in situ* and following their *in vitro* cell

differentiation from TS cells.

To assess impacts on EVT cell development, we stably expressed shRNAs specific to

each TF in the stem state and then attempted to differentiate the cells into EVT cells using CT27

(**Figs. 8-9**) and CT29 cell lines (**Supplementary Figs. 22-23**). shRNAs were identified that

significantly inhibited *SNAI1* expression at transcript (**Fig. 8a**, **Supplementary Fig. 22A**) and

protein levels **(Fig. 8b, Supplementary Fig. 22b)**. Similarly, *EPAS1*-specific shRNAs

significantly inhibited expression at transcript (**Fig. 9a**, **Supplementary Fig. 23a**) and protein

levels (**Fig. 9b**, **Supplementary Fig. 23b**) in CT27 and CT29 cell lines, respectively.

Knockdown of either *SNAI1*, or *EPAS1* were each compatible with maintenance of the TS cell

stem state. However, deficits in each TF negatively affected aspects of EVT cell differentiation

(**Fig. 8c**, **Supplementary Fig. 22c**), with *EPAS1* disruption showing the most extensive

morphologic impact (**Fig. 9c, Supplementary Fig. 22c**). *EPAS1* knockdown cells consistently

failed to exhibit the characteristic elongation normally associated with EVT cell differentiation.

Parameters of EVT cell differentiation in control and TF knockdown cells were further

investigated using RNA-Seq which revealed that both TFs contributed to the regulation of

several genes associated with EVT cell lineage development (**Figs. 8-9**). *SNAI1* disruption led

to downregulation of several genes associated with the EVT cell state (e.g., *FLT4, LAMA4,*

IGF2, *ISM2*, *ASCL2*, *FSTL3*, *DLX6*, and *NOTUM*) and upregulation of EVT cell interferon-

responsive transcripts (e.g., *IFIT1, IFIT2, IFIT3, IFITM1, IFI27, IFI35, IFIH1, OAS2, OAS3,* and

MX1) as well as several stem state-associated transcripts (e.g., *ITGB6*, *GJA1*, *LAMB3*, *F3*, and

TAGLN) (**Fig. 8d**). Similar transcriptomic changes were observed in CT29 cells following *SNAI1*

disruption (**Supplementary Fig. 22d**). IFN-responsive transcript expression appears to be a

feature of human trophoblast cell differentiation[49] and may be associated with repetitive element

expression and double stranded RNA stress[50]. Similar to morphological changes, disrupting

EPAS1 had the most extensive impact on the EVT cell transcriptome. Signature EVT cell-

specific transcripts were prominently downregulated (e.g., *NOTUM*, *DIO2*, *HTRA1*, *MMP2*,

PDE6H, *ADAM12*, *MCAM*, *HLA-G*, *ASCL2*, *DLX6*, *DLX5*, *ISM2*, *CCR1*, *SNAI1*, *ITGA1*, and

GCM1). *GCM1* was recently reported to play an important role in EVT cell development[51]. In

addition, several stem state markers (*ITGB6*, *LAMB3*, *F3*, *JUN*, *EGLN3*, *CYR61*, and *NPPB*)

were upregulated in *EPAS1* disrupted cells (**Fig. 9d**). Similar transcriptomic changes were

observed in CT29 cells following *EPAS1* disruption (**Supplementary Fig. 23d**). In summary,

disruption of *SNAI1* or *EPAS1* each resulted in downregulation of EVT cell-specific transcripts.

Differences among the activities of each TF as a transcriptional repressor versus

activator (calculated based on Log2FC>3 or <-3) were evident. *SNAI1* and *EPAS1* had

repression to activation ratios of 70:30 and 60:40, respectively. The known repressor actions of

SNAI1[52] are consistent with the profile.

In addition to the common feature of the TFs impacting known EVT-cell markers, each

TF also contributed to the regulation of unique transcript signatures. In fact, pathway analysis

performed on the top 500 significantly altered (upregulated or downregulated) genes upon

silencing of each TF revealed that the most significant biological function associated with the

differentially regulated genes for both TFs was "Migration of Cells" (*SNAI1*: p=1.5E-39; *EPAS1*:

p=8.3E-49; **Supplementary Table 12, Supplementary Table 13**). Additional pathway analysis

performed on the subset of *EPAS1* gene targets mapping to the "Migration of Cell" function

(n=209 genes) identified "Invasion of Cells" as another top function (p=5.3E-70). Many genes

mapping to this "Invasion of Cells" cluster are known contributors to the regulation of EVT cell

invasion into the uterus (**Supplementary Fig. 21b**).

EPAS1 is an upstream TF regulator and dysregulated in placenta failure

As noted in the functional assays, *EPAS1* disruption had the greatest impact on EVT cell

morphology and resulted in the downregulation of multiple key genes involved in EVT cell

differentiation and invasion. To test the potential of *EPAS1* to act as a direct transcriptional

regulator, we used ATAC-Seq peaks containing *EPAS1* (HIF2A) motifs in EVT cells and

intersected with RNA-Seq data from control and *EPAS1* knockdown cells (**Supplementary**

Table 14). This analysis identified *EPAS1*-regulated genes, as detected by RNA-Seq analysis

(log2 foldchange <-1; adjusted p<0.05), being significantly correlated with chromatin accessible

regions containing *EPAS1* (HIF2A) binding motifs. This corresponded to a 1.5-fold enrichment

(Chi^2=62; Fisher p<0.0001) when considering all EVT cell peaks and a 2.5-fold enrichment

when restricting to those EVT cell peaks with differential binding affinity (Chi^2=71; Fisher

p<0.0001). Among these putative direct targets of *EPAS1* action were *PLAC8*, *DIO2*, *MMP2*,

MYCN, *ADAM12*, *HLA-G*, and *DLX6.*

As failure of proper EVT cell invasion into the uterine compartment at the maternal fetal

interface may lead to pregnancy complications, we next assessed whether there is evidence

linking *EPAS1* to adverse pregnancy outcomes such as pregnancy loss[53]. To this end, single-

cell gene expression data was generated from first trimester placental samples (4,787 cells)

derived from individuals suffering from idiopathic RPL. Single EVT cells (n=194) were profiled,

and expression profiles were compared to compatible single-cell expression profiles of EVT

cells (n=693) from gestational age-matched normal control placental samples (**Supplementary**

Fig. 24). Of the 2,967 differentially expressed genes (absolute log2fold change >1, adjusted

p<0.05) identified in EVT cells isolated from RPL specimens (**Supplementary Table 15**),

EPAS1 was ranked among the top 200. Further, *EPAS1* expression was significantly higher in

placentas from RPL patients (log2fold change=1.6, adjusted p=7.2E-9, **Fig. 9f**).

To assess the potential role of *EPAS1* in gene expression dysregulation in RPL, a

comparison was performed between upregulated genes identified in EVT cells derived from

RPL placentas (log2 fold change >1; adjusted p<0.05) and genes downregulated by *EPAS1*

disruption in TS cell-derived EVT cells (log2 fold change <-1; adjusted p<0.05). This comparison

identified a 1.7-fold enrichment (Chi^2=53; Fisher p<0.0001) indicative of common gene targets.

Among these genes (i.e., upregulated in RPL and positively regulated by *EPAS1* during EVT

cell differentiation) were *NOTUM*, *DIO2*, *ADAM12*, *ITGA1*, *CSH1*, *PAPPA*, *PAPPA2*, *CDKN1C*,

LIFR, *FN1,* and *FLT1*. Upregulation of *FLT1* has been shown to be linked to *EPAS1*

upregulation during hypoxia-induced placental failure[54] and upregulation of *CDKN1C* has been

observed in placental samples derived from pregnancy loss cases[53]. In all, these RPL

associated changes in *EPAS1* driven EVT cell gene expression may reflect an adaptive

response of a failing pregnancy. A healthy placenta can be defined by its ability to effectively

adapt to stressors within the uterine environment[55]. Pregnancy failure in RPL may be

exacerbated because EPAS1 driven adaptations are insufficient to sustain the pregnancy.

Genetic variants at the EPAS1 locus are linked to pregnancy complications

To test the hypothesis of a potential genetic predisposition for pregnancy loss, we

accessed summary statistics from genome-wide association studies (**GWAS**) of related

phenotypes available in the UK Biobank. In addition to pregnancy loss phenotypes, we also

included analysis of maternal and fetal genetic effects on birth weight (**Supplementary Table**

16) as failure of the placenta can result in fetal growth restriction as well. Using these

phenotypes, we computed the odds ratio of the proportion of nominally significant (p<0.05) hits

in the *EPAS1* gene region (chr2:46,150,000-46,450,000) encompassing our regulatory elements

compared with variants in a randomly selected matched window. We found a striking

enrichment of *EPAS1* genetic variants for not only pregnancy loss but also for birth weight

compared to background (**Fig. 9e; Supplementary Fig. 21a; Supplementary Fig. 25;**

Supplementary Table 17). While there is to our knowledge no other large-scale GWAS done

on pregnancy loss that can be used for additional replication, we accessed summary statistics

from an independent, similar sized GWAS of birth weight[56] (N=321,223) and were able to

confirm the effect of the *EPAS1* locus (rs17034876; p_{UKBB}=7.1E-28 and $p_{Warrington}$=3.1E-47).

Finally, we used all loci associated with birth weight (N=273 genes, p<0.001) and found a

significant link (1.9-fold change, Chi^2=32.7; Fisher p<0.0001) between fetal genetic loci for birth

weight and genes dysregulated by *EPAS1* disruption (absolute log2fold change >1, adjusted

p<0.05). Genes included not only *EPAS1* itself (**Fig. 9e** and **Supplementary Fig. 21a**), but also

FLT1, PAPPA, PAPPA2, and *CDKN1C* (**Supplementary Table 18**)*.*

To conclude, these predisposing *EPAS1* genetic variants associated with pregnancy

complications may lead to EPAS1 dysregulation, abnormalities in transcriptional control, and

ineffective placentation leading to increased risk of placental disorders. However, further

mechanistic, and population-based studies are needed to establish these relationships.

DISCUSSION

EVT cell invasion into the uterine compartment is a critical component of spiral artery

remodeling and successful pregnancy[2,57]. Despite our understanding of the importance of EVT

cell function, our knowledge of the underlying molecular mechanisms driving EVT cell

development is limited. Here, we utilized the human TS model[22] to track regulatory events

controlling EVT cell differentiation and generated an NGS-based functional genomics resource

comprising atlases for transcriptomes by RNA-Seq, open and active chromatin by ATAC-Seq

and ChIP-Seq of histone modifications, and chromatin interactions by Hi-C. Although, all *in vitro*

models have limitations, human TS cells represent a remarkable high fidelity stem cell system

with the capacity to exhibit many traits intrinsic to EVT cells developing *in situ*. Later stages of

differentiation associated with EVT cells penetrating the uterine parenchyma are unlikely to be

captured as well in this cell culture model and would require additional refinements.

The NGS datasets from the TS model were used to identify higher order regulatory events driving EVT cell lineage specification including characterization of signature epigenomic landmarks characteristic of EVT cell lineage development. Global epigenomic events were reinforced by inspection at the level of individual genes known to drive EVT cell differentiation (e.g., *ASCL2*)[20] and downstream genes responsible for the phenotypic features of an EVT cell (e.g., *MMP2,* and *HLA-G*).

The architecture of the epigenome undergoes profound changes as stem cells differentiate into specialized cells[58,59]. The transformation is apparent at multiple levels. Some chromatin regions become more accessible and other regions are closed to the requisite machinery controlling gene transcription. This regulatory process is facilitated by formation of chromatin loops allowing for long-range interactions of regulatory elements including enhancers and promoters. The net effect is distinct transcript profiles associated with stem versus differentiated cells, resulting in cells possessing different morphologies and functional attributes. These architectural and functional changes are exemplified in human TS cells differentiating into EVT cells. TS cells cultured in the stem state are tightly associated, and cellular efforts are directed to proliferation, whereas differentiation into EVT cells is characterized by cell colony dispersal, the manifestation of prominent cellular extensions, and cell migration. Trophoblast cell differentiation status is further defined by cell-specific patterns of gene expression, chromatin accessibility and long-range chromatin interactions – all occurring in a coordinated manner. This new map of trophoblast-lineage specific regulatory DNA generated here consists not only of distinct active chromatin regions specific to EVT cells but also extends current maps of open chromatin for human cell types and tissues[29]. Increased chromatin accessibility in EVT cells was enriched in intronic and intergenic regions and linked to increased RNA expression. These observations are in line with reference epigenome mapping efforts[29] and point towards pronounced activity of distal regulatory regions (i.e., enhancers) controlling cell lineage development through involvement of master TFs regulating gene expression in EVT cells.

Indeed, the appearance of increased enhancer-driven gene regulation in EVT versus stem state

cells were confirmed by ChIP-Seq of histone modifications marking active enhancer regions

(H3K27ac).

Motif enrichment within chromatin accessible regions revealed potential 'core' TF-DNA

interactions that define the EVT developmental state including *TEAD3* and *TFAP2C*. *TEAD3*

was identified in a large integrative analysis of over 100 cell types to bind to enhancers that

were specific to embryonic stem cell differentiated into trophoblast by treatment with bone

morphogenetic protein 4[29]. *TFAP2C* is a known regulator of the mouse TS cell stem state[6,9].

Consistent with these observations we showed that *TFAP2C* is also critical for human TS cell

expansion and the onset of EVT cell differentiation. In addition, *TFAP2C* represents a key factor

in the derivation of TS cells from fibroblasts and pluripotent stem cells[15,16,46,60]. A recent

CRISPR-Cas9 screen has identified other transcriptional regulators critical to maintaining the TS

cell stem state (*ARID3A*, *GATA2*, *TEAD1*, and *GCM1*)[43].

Our genome-wide integrative analyses with multiple layers of epigenome information

including active regulatory regions and their interactions led to the identification of an

established TF regulator of EVT cell development, *ASCL2*[20]. The epigenomic landscape of

ASCL2 changed as trophoblast cells differentiated from the stem state to EVT cells. This

transition was characterized by the appearance of a long-range interaction of a super-enhancer

with the *ASCL2* promoter. We also identified compelling new TF candidates controlling EVT cell

lineage development including *SNAI1, DLX6*, *MYCN*, and *EPAS1* – each possessing

epigenomic signatures indicative of gene activation in both cultured EVT cells and primary EVT

cells. Silencing of *SNAI1* resulted in disruptions in EVT cell development and affected the

expression of a subset of transcripts characteristic of EVT cells. *SNAI1* is an established

transcriptional repressor with known roles in promoting epithelial to mesenchymal transition[52],

including a potential involvement in EVT cell development[61]. *EPAS1* encodes hypoxia inducible

factor 2 alpha (**HIF2A**), a basic helix-loop-helix domain TF, coordinating cellular responses to

low oxygen and developmental processes with a connection to trophoblast cell biology[62]. The actions of *EPAS1* on EVT cell development were much more extensive than observed for *SNAI1* and included transcriptional regulation of virtually all transcripts defining the EVT cell phenotype. Interestingly, these transcriptional *EPAS1* targets also included TFs contributing to the regulation of EVT cell differentiation (e.g., *ASCL2* and *SNAI1*). Thus, *EPAS1* can be placed upstream relative to other transcriptional regulators directing EVT cell differentiation (**Fig. 9G**). *EPAS1* mRNA and protein accumulate as EVT cells differentiate and do so independent of low oxygen tensions. Mechanisms controlling EVT cell dependent *EPAS1* transcriptional activation and *EPAS1* (HIF2A) protein stabilization are unknown. Elucidation of factors controlling EVT cell *EPAS1* will add to understanding the regulation of EVT cell differentiation.

The biology of *EPAS1* in placentation is complicated. *EPAS1* expression is not restricted to EVT cells. Syncytiotrophoblast also express *EPAS1*[63,64]. Thus, additional layers of regulation impart specificity for *EPAS1* actions in EVT cells versus syncytiotrophoblast. These disparate actions may be linked to contributions of cell specific co-regulators[65,66], canonical versus non-canonical *EPAS1* signaling[67], or the involvement of other unappreciated modulator(s) of *EPAS1* action. The relevance of *EPAS1* to placentation is evident in its association with placental disease. RPL is characterized by elevated EVT cell *EPAS1* expression. *EPAS1* is also dysregulated in preeclampsia[68]. Under such circumstances, *EPAS1* may be responding to a failed placenta and the ensuing hypoxia. Context is important, and inappropriate *EPAS1* may hinder rather than support placentation. Compromised placental function negatively impacts fetal growth, which is also connected to misexpression of *EPAS1* gene targets and is demonstrated by genetic linkage to low birth weight[56].

In summary, we have provided insights into a trophoblast regulatory network controlling EVT cell lineage development. Datasets generated from this research represent a resource for developing new hypotheses that can be tested *in vitro* with human TS cells and *in vivo* using appropriate animal models. They will also provide a valuable reference dataset for newly

established TS cell lines derived from pluripotent stem cells[46,69,70]. *TFAP2C*, *SNAI1*, and *EPAS1*

provide entry points and a framework for understanding EVT cell differentiation and human

placentation. The challenge will be to harness this new knowledge to develop effective

strategies for diagnosing and treating diseases of placentation.

MATERIALS AND METHODS

Human TS cell culture

Human TS cells (CT27, 46, XX and CT29, 46, XY)[22] were cultured in 100 mm tissue

culture dishes coated with 5 µg/mL collagen IV (CB40233, Thermo-Fisher, Waltham, MA).

Human TS cells were maintained in Complete human TS cell medium [DMEM/F12 (11320033,

Thermo-Fisher), 100 µm 2-mercaptoethanol, 0.2% (vol/vol) fetal bovine serum (**FBS**), 50 U/mL

penicillin, 50 µg/mL streptomycin, 0.3% bovine serum albumin (**BSA**, BP9704100, Thermo-

Fisher), 1% Insulin-Transferrin-Selenium-Ethanolamine solution (**ITS-X**, vol/vol, Thermo-

Fisher)], 1.5 µg/mL L-ascorbic acid (A8960, Sigma-Aldrich, St. Louis, MO), 50 ng/mL epidermal

growth factor (**EGF**, E9644, Sigma-Aldrich), 2 µM CHIR99021 (04-0004, Reprocell, Beltsville,

MD), 0.5 µM A83-01 (04-0014, Reprocell), 1 µM SB431542 (04-0010, Reprocell), 0.8 mM

valproic acid (P4543, Sigma-Aldrich), and 5 µM Y27632 (04-0012-02, Reprocell). EVT cell

differentiation was induced by plating human TS cells onto 6-well plates pre-coated with 1

µg/mL collagen IV at a density of 80,000 cells per well. Cells were cultured in EVT

Differentiation Medium [DMEM/F12 (11320033, Thermo-Fisher), 100 µm 2-mercaptoethanol,,

50 U/mL penicillin, 50 µg/mL streptomycin, 0.3% BSA, 1% ITS-X solution (vol/vol)], 100 ng/mL

of neuregulin 1 (**NRG1**, 5218SC, Cell Signaling, Danvers, MA), 7.5 µM A83-01 (04-0014,

Reprocell, Beltsville, MD), 2.5 µM Y27632, 4% KnockOut Serum Replacement (**KSR**,

10828028, Thermo-Fisher), and 2% Matrigel® (CB-40234, Thermo-Fisher). On day 3 of EVT cell

differentiation, the medium was replaced with EVT Differentiation Medium excluding NRG1 and

with a reduced Matrigel® concentration of 0.5%. On culture day 6 of EVT cell differentiation, the

medium was replaced with EVT Differentiation Medium excluding NRG1 and KSR, and with a

Matrigel concentration of 0.5%. Cells were analyzed in the stem state and at days 3, 6, and 8 of

EVT cell differentiation.

Cells were harvested from plates with trypsin, counted, and viability determined with a

Countess II automated cell counter (Thermo-Fisher). Sample replicates with the highest viability

and an adequate cell count were selected to be used for ATAC-Seq. Cells used for RNA

isolation were centrifuged at 300 g for 8 min, supernatants were removed, and cell pellets were

resuspended in 1 mL of TRIzol (15596026, Thermo-Fisher).

Flow cytometric analysis

Cells in culture were washed with phosphate buffered saline (**PBS**), detached with

TrypLE Express (12604021, Thermo-Fisher Scientific), and collected in basal culture medium.

Cell suspensions were centrifuged, cell pellets were washed with PBS, and resuspended with

4% paraformaldehyde in PBS for 20 min at room temperature with gentle agitation. Fixed cell

suspensions were centrifuged, and cell pellets were washed twice with PBS and stored at 4°C.

Fixed cells were permeabilized with PBS containing 3% BSA and 0.2% Triton X-100 for 30 min

at room temperature with gentle agitation. Cells were washed with PBS and blocked with PBS

containing 3% BSA for 15 min and then incubated overnight with anti-HLA-G-phycoerythin

(1:1500, 1P-292-C100, Cedarlane Labs) prepared in PBS containing 3% BSA and 0.2% Triton

X-100 in the dark at 4°C with gentle agitation. Cells were washed twice with PBS, filtered, and

analyzed using a BD LSR II flow cytometer (BD Biosciences) at the University of Kansas

Medical Center (**KUMC**) Flow Cytometry Core Laboratory.

Omni-ATAC library preparation, sequencing, and analysis

The Omni-ATAC library preparation was performed on freshly isolated cells according to an established protocol[71] until the post-transposition cleanup step. After cleanup of the transposed DNA was complete, samples were stored at -20°C until library amplification. Samples were subsequently thawed at room temperature and library construction completed. The samples underwent 5 cycles of PCR before an aliquot was used in a quantitative PCR (**qPCR**) reaction to determine whether additional amplification was required. An Applied Biosciences Viia7 Real-Time PCR System (Applied Biosciences, Beverly Hills, CA) was used for qPCR and the number of additional PCR cycles needed was determined from the multicomponent plot, which plots fluorescence versus the number of PCR cycles. The maximum fluorescence for each sample was found from the plot, ¼ of the maximum fluorescence value was calculated, and the number of additional PCR cycles needed was calculated by determining the cycle number that reached ¼ maximum fluorescence on the graph. In cases where the ¼ maximum fluorescence value was halfway between two cycle numbers, the lower number of cycles was selected since slight under-amplification was more favorable than overamplification. The original samples were then PCR amplified with their determined number of additional cycles. Cleanup of the samples was performed after PCR amplification according to the published protocol[71]. Libraries were quantified using a Qubit dsDNA BR Assay Kit (Q32853, Thermo-Fisher) and the size was determined with a High Sensitivity DNA Bioanalyzer Kit (5067-4626, Agilent, Santa Clara, CA) and sequenced on an Illumina Nova6000Seq paired-end using Nextera Sequencing primers.

Basic quality control of raw FASTQ files was performed using HTStream (Version 1.3.2; https://github.com/s4hts/HTStream). PhiX reads were removed using hts_SeqScreener with default parameters. Duplicates were removed using hts_SuperDeduper (-e 250000). Adapter sequences were trimmed with hts_AdapterTrimmer (-p 4). Unknown nucleotides (N) were

removed using hts_Ntrimmer. Base quality trimming was performed using a minimum average

quality score of 20 (-q 20) in a 10-bp sliding window (-w10) with hts_QWindowTrim. Trimmed

reads shorter than 50 bp as well as orphaned reads from a pair were removed using

hts_LengthFilter (-n -m 50). Reads were aligned to the human genome (GRCh38.86) using

BWA mem (Version 0.7.17-r1188). The alignments were shifted using alignmentSieve

(deepTools; Version 3.5.1) using the --ATACshift option. Alignments in the ENCODE blacklisted

regions (https://doi.org/10.5281/zenodo.1491733) were removed using Bedtools intersect (with

option `-v`; Version 2.30.0). Peaks for each sample were called independently using the

callpeak function in MACS3 (Version 3.0.0a6) with a minimum FDR of 0.01 (-q 0.01). Peak

regions were annotated in regard to the genomic feature of their location using HOMER's

annotatePeaks.pl script as well as overlap with DNAse I hypersensitive sites (min overlap of

1bp)[29]. Unique peaks (e.g., EVT cell) were determined based on complete lack of overlap with a

comparing set of peak regions (e.g., stem state).

The webtool GREAT was used to retrieve genes with an overlapping regulatory domain,

where the regulatory domain of a gene is the region 5 kb upstream and 1 kb downstream of the

transcription start site (**TSS**). Additionally, distal gene elements were retrieved where the

regulatory domain of the genes extends up to 1 Mb. Finally, each peak was annotated by

mapping it to the most significant differentially expressed gene (EVT vs stem) with a TSS within

10 kb of the peak region.

ATAC-seq read counts per peak were generated using the Bioconductor package

DiffBind (Version 3.2.7). Peaks with less than 10 counts per million (**CPM**) were excluded. The

differential binding affinity of a region between EVT and stem samples was assessed in the

Bioconductor package limma (Version 3.48.3) with an FDR of 0.05.

Super-enhancers were called using HOMER (version 4.7.2) findpeaks

(http://homer.ucsd.edu/homer/ngs/peaks.html) using "-style super" mode.

RNA library preparation, sequencing, and analysis

RNA was isolated with a TRIzol/chloroform precipitation followed by a cleanup with a

RNeasy Mini Kit (74104, Qiagen, Germantown, MD). Frozen cell isolates in TRIzol were thawed

on ice prior to starting the isolation. Once thawed, the samples were placed at room

temperature for 5 min to promote dissociation of nucleoprotein complexes. Next, 200 µL of

chloroform was added to each sample with vigorous shaking for 15 sec. Samples were placed

at room temperature for 3 min before centrifugation at 12,000 g for 15 min at 4°C. After

centrifugation, the upper, colorless, aqueous phase was removed and transferred to a new 1.5

mL tube and 1.5 volumes of 100% ethanol added. Isolates containing ethanol were mixed

thoroughly by pipetting and 650 µl transferred to a RNeasy spin column. The protocol for the

RNeasy Mini Kit was then followed to clean the sample post-TRIzol/chloroform extraction. RNA

was then quantified using a Qubit RNA BR Assay Kit and RNA integrity assessed using RNA

ScreenTape (5067-5577 and 5067-5576, Agilent) on the Agilent TapeStation platform (Agilent)

prior to library preparation.

RNA libraries were prepared using a TruSeq Stranded RNA HT Sample Prep Kit (RS-

122-2303, Illumina on a Caliper Sciclone G3 platform (PerkinElmer, Waltham, MA). Manual

bead cleanup was performed using AMPure XP Beads (A63881, Beckman Coulter, Brea, CA)

after library preparation to remove primer-dimers. 1.0x volume of beads was added to the entire

library volume. Samples were mixed by pipetting and incubated at room temperature for 5 min

before being placed on a magnetic stand until the supernatant cleared. Once clear, the

supernatant was removed and discarded, and the beads were washed twice with 80% ethanol

while still on the magnet. Any residual ethanol was removed, and the beads were air-dried on

the magnet for 5 min at room temperature. Once dry, 30 µL of Resuspension Buffer was added

to each sample, the beads were resuspended by pipetting, and the solution incubated for 2 min

at room temperature. Samples were then placed on a magnet until the supernatant was clear.

The supernatant was then transferred to a new plate. A Qubit dsDNA BR Assay kit was used to

determine the concentration of the library and a Fragment Analyzer Standard Sensitivity NGS

Fragment Kit (DNF-473-10000, Agilent) was used to detect the size of the library and to verify

removal of excess primer-dimers. Standard Illumina Free-Adapter Blocking was performed on

the libraries. Cleaned, adapter-blocked libraries were loaded on a NovaSeq6000 (Illumina, San

Diego, CA) with a run configuration of 151x8x8x151 and an average depth of 70 M paired-end

reads per library.

Raw FASTQ files were trimmed using default parameters (-r 0.1 -d 0.03) in Skewer

(Version 0.2.2) and reads shorter than 18 bp were discarded. Transcripts were quantified using

Kallisto (Version 0.46.2). Differentially expressed genes at FDR of 0.05 were discovered using

the Bioconductor package DESeq2 in R (Version 1.32.0). CT27 and CT29 RNA-sequencing

data were processed individually following standard processing.

18   *Histone modification ChIP-Seq and analysis*

ChIP was performed on CT27 human TS cells as previously described[22] using

commercially available ChIP Reagents (Nippon Gene, Tokyo, Japan). The following antibodies

were used: H3K4me3 (Clone No. CMA304, MABI0304, MBL International, Woburn, MA), and

H3K27ac (MABI0309, Clone No. CMA309, MBL International). The ChIP-Seq library was

constructed using the Ovation Ultralow System V2 (NuGEN Technologies, Redwood City, CA)

and sequenced on the Illumina HiSeq 2500 platform (Illumina). Basic quality control of raw

FASTQ files was performed using HTStream (Version 1.3.2;

https://github.com/s4hts/HTStream). PhiX reads were removed using hts_SeqScreener with

default parameters. Duplicates were removed using hts_SuperDeduper (-e 250000). Adapter

sequences were trimmed with hts_AdapterTrimmer (-p 4). Unknown nucleotides (N) were

removed using hts_Ntrimmer. Base quality trimming was performed using a minimum average

quality score of 20 (-q 20) in a 10-bp sliding window (-w10) with hts_QWindowTrim. Trimmed

reads shorter than 50 bp as well as orphaned reads from a pair were removed using

hts_LengthFilter (-n -m 50). Reads were aligned to the human genome (GRCh38.86) using

BWA mem (Version 0.7.17-r1188). Alignments in the ENCODE blacklisted regions

(https://doi.org/10.5281/zenodo.1491733) were removed using Bedtools intersect (with option `-

v`; Version 2.30.0). Peaks for each sample were called independently using the callpeak

function in MACS3 (Version 3.0.0a6) with a minimum FDR of 0.01 (-q 0.01).

Chromatin capture by Hi-C

Cells were rinsed with 5 mL of PBS and then 5 mL PBS containing 2% formaldehyde

were added and incubated for 10 min. Then, 550 µL of glycine 1.25 M (final conc 0.125M) were

added and incubated for 5 min at room temperature before an additional 15 min incubation on

ice. Liquid was removed and cells were rinsed two times with 5 mL ice-cold PBS. Cells were

scraped and transferred into 2 mL low bind tubes to have the equivalent of 1*10^6 cells (1 Petri

Dish). Nuclei were pelleted at 2,500 rpm for 10 min at 4˚C (repeat if necessary) and all

supernatant was removed and flash frozen on dry ice and stored at -80˚C until ready for use.

Crosslinked samples were thawed on ice and prepared for Hi-C using the Arima-HiC kit (Arima

Genomics, San Diego, CA). Cross-linking was performed according to the Arima-HiC protocol

with the following modifications. At step 5, the incubation at 37°C was increased to a duration of

60 min and the samples were maintained overnight at 4°C after step 11. Samples were then

cleaned with AMPure XP Beads as described in the protocol and all quantification and quality

control steps that required the use of a Qubit were performed using a Qubit dsDNA HS Assay

Kit. Proximally ligated DNA (1000 ng/sample) was used as an input into the library preparation

protocol. Samples were sheared to 400 bp using a Covaris LE220-plus system using the

manufacturer's recommended settings. Sizing was confirmed using a High Sensitivity DNA

Bioanalyzer kit. Size-selection as described in the Arima-HiC protocol was followed and the

entire size-selected sample was used as input into biotin enrichment and library preparation with

a KAPA HyperPrep kit and Roche SeqCap Adapters (7141530001 or 7141548001, Roche).

Instead of performing the Arima-HiC quality control step 2, the number of cycles needed for

library amplification was determined as follows: perform 10 PCR cycles for 125-200 ng of input,

perform 9 PCR cycles for 200-400 ng of input, perform 8 PCR cycles for 400-600 ng of input,

and perform 7 cycles of PCR for inputs greater than 600 ng. The completed libraries were then

quantified using a Qubit dsDNA BR Assay Kit and the library size was determined with a High

Sensitivity DNA Bioanalyzer Kit. Standard Illumina Free-Adapter Blocking was performed on the

libraries. Cleaned, adapter-blocked libraries were loaded on a NovaSeq6000 with a run

configuration of 151x8x8x151 and an average depth of 900M PE reads per library.

To discover chromatin loops the standard Juicer pipeline[39] was used where contact

maps for each sample were generated using the Arima Genomics fragment map file specific to

GRCh38 and default parameters. After merging contact maps for each cell state, stem and EVT,

chromatin loops were discovered with HiCCUPS (Juicer Tools Version 1.22.01;[39]) using a matrix

size of 1000 (-m 1000) at 5kb, 10 kb, and 25 kb resolution (-r 25000,10000,5000). Differential

loops between EVT and stem were identified using HiCCUPSDiff (Juicer Tools Version

1.22.01;[39]) with a matrix size of 1000 (-m 1000). The chromatin loops as well as the differential

loops were filtered to exclude contacts in the ENCODE blacklisted regions ([72];

https://doi.org/10.5281/zenodo.1491733) using Bedtools intersect (with option `-v`; Version

2.30.0;[73]). Furthermore, genes with a TSS within 10 kb of a loop region were linked to each

loop.

The Bedtools toolkit was used to compute the depth of coverage of the ATAC read data

genome-wide in 100 bp bins, normalizing number of ATAC reads in each bin for every 10 M

total reads for a given sample. All bins within 20 kb of either end of each of the EVT and stem

cell loops were then extracted. To generate control sets, 1000 randomly selected intervals

(chose from chr1-22, X, Y) that do not intersect any of the loops and do not intersect our list of

blocked regions were generated. Three different control sets with intervals of size 5 kb, 10 kb

and 25 kb were generated. All ATAC bins within 20 kb of the intervals in each of these control

sets were extracted.

Aggregate contact plots were generated with hicAggregateContacts (HiCExplorer

Version 3.7.2)[74] using intra-chromosomal contacts at the 5-kb resolution. Number of bins was

set to 20 and the "obs/exp" transformation was used for the contact matrix. Heatmaps were

generated with Juicebox 1.11.08.

Transcription factor motif analysis

Motif analysis for ATAC-Seq data was performed using HOMER's findMotifsGenome.pl

script (option '-size-given200'; Version 4.11). Motif analysis for Hi-C data in the chromatin

contact regions were also discovered using HOMER's findMotifsGenome.pl script (option '-size

given'; Version 4.11;[75]).

TFAP2C ChIP-Seq and analysis

ChIP was performed on CT27 human TS cells[22] in three replicates using the SimpleChiP

Enzymatic Chromatin IP kit (Cell Signaling Technology . Anti-rabbit AP-2 gamma antibodies

(2320, Cell Signaling) was used in the analysis. In total of 100 ng of fragmented DNA in 25 µL of

water was used as input in library preparation. A KAPA HyperPrep Kit (07962347001, Roche)

was used for library preparation, following the protocol associated with the kit with the following

modifications. During end repair and a-tailing, 35 µL of water was added to the master mix

containing 7 µL of end-repair and a-tailing buffer and 3 µL of end-repair and a-tailing enzyme.

Forty-five µL of the end-repair and a-tailing master mix was added to each sample and was

mixed thoroughly by pipetting. During the adapter ligation step, Illumina TruSeq DNA LT

adapters, supplied at 15 µM, were diluted 1:100 in water and 5 µL of diluted adapters were

added to the sample. A master mix of 30 µL of ligation buffer and 10 µL of DNA ligase was

made and 40 µL of ligation master mix was added to each sample. After adapter ligation, a 0.8x

bead clean-up was performed using AMPure XP Beads (A63881, Beckman Coulter) with a 10

min incubation at room temperature to allow the DNA to bind to the beads and a 7 min

incubation after two 80% ethanol washes to allow the beads to dry. Once the beads were dry,

the beads were resuspended in 25 µL of water and incubated at room temperature for 2 min.

Twenty µL of post-ligation sample was then transferred to a new tube to be used in library

amplification. The PCR library amplification master mix consisted of 25 µL of 2x KAPA HiFi

HotStart ReadyMix, 1.5 µL of 10x PCR primer cocktail, and 3.5 µL of water. Thirty µL of the

PCR master mix was added to each post-ligation sample and 13 cycles of PCR were

performed. After library amplification, the library underwent a 0.6/0.8x double-sized size

selection with 10 min incubations to allow the library to bind to the beads. Two 80% ethanol

washes were performed, and the beads were allowed to dry at room temperature for 2 min.

Thirty-six µL of water was added to the dried beads and was incubated at room temperature for

min to elute the DNA. Thirty-four μL of the final, size-selected library was transferred to a new

tube. The final library concentration was assessed with a Qubit dsDNA HS Kit (Q32854,

Thermo-Fisher), and the final size was determined, centering at approximately 400 bp, with a

D1000 ScreenTape and D1000 reagents (5067- 5582 and 5067- 5583, Agilent). Cleaned,

adapter-blocked libraries were loaded on a NovaSeq6000 with a run configuration of

151x8x8x151 and sequenced to an average depth of 20M PE reads per library. Basic quality

control of raw FASTQ files was performed using HTStream (Version 1.3.2;

https://github.com/s4hts/HTStream). PhiX reads were removed using hts_SeqScreener with

default parameters. Duplicates were removed using hts_SuperDeduper (-e 250000). Adapter

sequences were trimmed with hts_AdapterTrimmer (-p 4). Unknown nucleotides (N) were

removed using hts_Ntrimmer. Base quality trimming was performed using a minimum average

quality score of 20 (-q 20) in a 10-bp sliding window (-w10) with hts_QWindowTrim. Trimmed

reads shorter than 50 bp as well as orphaned reads from a pair were removed using

hts_LengthFilter (-n -m 50). Reads were aligned to the human genome (GRCh38.86) using

BWA mem (Version 0.7.17-r1188). Alignments in the ENCODE blacklisted regions

(https://doi.org/10.5281/zenodo.1491733) were removed using Bedtools intersect (with option `-

v`; Version 2.30.0). Peaks for each sample were called independently using the callpeak

function in MACS3 (Version 3.0.0a6) with a minimum FDR of 0.01 (-q 0.01).

Single-Cell RNA Analysis

<u>Sample Collection and Processing</u>

Study participants were screened at the University of Kansas Health System Advanced

Reproductive Medicine Clinic. Inclusion criteria was age >18 years and <42 years at the time of

conception, BMI >18 kg/m^2 and <30 kg/m^2, and a history of unexplained RPL with recent

diagnosis of miscarriage. Diagnosis of RPL was made using recommendations by the American

Society for Reproductive Medicine Practice Committee[76] with RPL defined as "spontaneous loss

of two or more pregnancies." For all patients known etiologies for miscarriage were ruled out

before allowing participation in study including: Mullerian anomaly, polycystic ovary disease,

thyroid disease, diabetes, coagulopathy, balanced translocation or structural rearrangement

from sperm or oocyte contributor, and obesity. Miscarriage was diagnosed using American

College of Obstetrician and Gynecologists Committee on Practice[77], which defines miscarriage

as "a nonviable, intrauterine pregnancy with either an empty gestational sac or a gestational sac

containing an embryo or fetus without fetal cardiac activity within the first 12 6/7 weeks of

gestation." All study participants had transvaginal ultrasound to confirm diagnosis of

miscarriage.

Product of conception (**POC**) including placental and decidual tissue were collected from

the study participants where all samples had normal karyotype based on clinical cytogenetics

testing including chromosomal analysis (GTG banded chromosomes analyzed at the 450-550

band levels) and array comparative genomic hybridization performed in accordance with current

International Standing Committee on Human Cytogenetic Nomenclature (ISCN 2009)

(**Supplementary Table 19**).

Each sample was rinsed in PBS before the addition of 5 mL of Digestion Medium

[DMEM/F12 (11320033, Thermo-Fisher) with 10% FBS, and 100 units/mL of penicillin and 100

µg of streptomycin (15140122, Thermo-Fisher) with 2.0 mg/mL collagenase type 1A] and

incubated for 50 min at 37ºC. The sample was strained through a pre-wetted 100 µm filter in a

50 mL conical tube and rinsed twice with 5 mL of DMEM/F12 with 10% FBS and 100 units/mL

penicillin and 100 µg/mL streptomycin and centrifuged at 300 x g for 8 min. Cell pellets were

resuspended in 1 mL of cold Recovery Cell Culture Freezing Medium (12648010, Thermo-

Fisher), and the cell suspension was transferred to a cryogenic storage vial. The cryogenic

storage vial was placed in a Corning CoolCell FTS30, which was then placed in a -80°C freezer

overnight. Samples were stored at -80°C before being thawed and processed for single-cell

RNA-Seq.

10X Genomics single-cell capture and sequencing

Prior to single-cell capture, samples were thawed in 10 mL of Thawing Medium

consisting of DMEM/F-12 (11320033, Thermo-Fisher) supplemented with 10% FBS and 100

units/mL of penicillin and 100 µg/mL of streptomycin (15140122, Thermo-Fisher) that was

prewarmed in a 37°C bead bath and centrifuged at 300 x g for 8 min. The supernatant was

carefully removed without disturbing the cell pellets. The cell pellets were each resuspended in

0.5 mL of Thawing Medium, and the cell suspensions were placed on ice and passed through a

pre-wetted 40 µm nylon mesh cell strainer. Cell suspensions were centrifuged at 300 x g for 8

min at 4°C, and the supernatant was carefully aspirated without disturbing the cell pellets. The

cell pellets were resuspended in 100 µL of cold Thawing Medium, and cell count and viability

were assessed using 0.4% Trypan Blue and a Countess II automated cell counter. For each

sample, Chromium Chip B (100153, 10x Genomics) were loaded (**Supplementary Table 19**).

Following cell loading, cDNA and library preparation was performed identically for all samples

using the Chromium Single Cell 3' Library & Gel Bead Kit v3 (1000075, 10x Genomics)

according to the manufacturer's protocol. Libraries were sequenced using an Illumina NovaSeq

6000 using 2x94 cycle paired-end. Sequenced reads were initially processed by the CellRanger

pipeline which includes FASTQ creation, read alignment, gene counting, and cell calling. The

Cell Ranger GRCh38(v2020-A) genome was used as the reference for alignment.

Post-sequencing analysis of single-cell RNA datasets

The Cell Ranger matrix file from the single-cell RNA sequencing (**scRNA-Seq**) of RPL

samples was processed along with the Cell Ranger matrices of two publicly available

datasets[27,28] of gestational age-matched normal control POC samples profiled using the same

platform (10X Genomics, **Supplementary Table 19**) using Seurat's standard workflow[78]. Each

sample was individually processed with the SCTransform function[79] using the glmGamPoi

package[80] with capture as a batch variable when applicable. The three datasets were integrated

using the standard integration workflow for data normalized with SCTransform[79] and 3,000

integration features were selected for downstream analysis. After integration, linear dimensional

reduction, nonlinear dimensional reduction, nearest neighbor finding, and unsupervised

clustering were completed according to the standard workflow[78]. Cell type label transfer was

performed by referencing the Vento-Tormo dataset[28]. The predicted cell identities (**ID**) were

generated using the FindTransferAnchors and TransferData functions of Seurat[78]. If necessary,

cell type labels were manually adjusted based on marker gene expression to exclude

ambiguous cell clusters. Cells with greater than 50% mitochondrial reads and less than 2,000

molecules were removed from all three datasets. The Vento-Tormo dataset[28] had an additional

filtering where cells with a mitochondrial ratio of greater than 20% and less than 3500 Unique

Molecular Identifiers (**UMIs**) and 1250 unique genes were removed.

Differential Expression Analysis

For differential expression analysis, genes were filtered according to the parameters

used for Vento-Tormo dataset[28]. The raw UMI counts of samples with multiple captures were

summed prior to differential expression analysis.

Genes that were expressed in three or more cells per dataset were kept for pseudobulk

differential expression analysis. A matrix was aggregated to find the UMI counts by gene per

sample ID within a specific cell type. Using the raw counts and metadata of a specific cell type,

a DESeq dataset[81] was created, and the counts were transformed by the vst function for

principal component analysis. Differential expression testing was performed by the DESeq

function with default parameters on the generated DESeq dataset[81]. Pairwise differential

expression contrasts were performed according to the inferred cell type labels (EVT or

SCT/VCT) where Vento-Tormo[28] and Suryawanshi[27] datasets were combined as the control

group. The contrast was performed with the results function from DESEq2 with default

parameters (Benjamini-Hochberg p-value adjustment) and alpha equal to 0.05[81]. Log2 fold

changes were shrunk with the lfcShrink function with the apeglm package[81,82]. For a gene to be

significantly differentially expressed, the Benjamini-Hochberg adjusted p-value was less than

0.05.

Gene Set Enrichment Analysis

The GSEA 4.3.2 software[83,84] was used using three gene sets (N=250 genes/set

representing upregulated genes from scRNA-Seq analysis in EVT and SCT/VCT, respectively,

as well as a gene set representing genes not differentially expressed). Normalized gene

expression count for each EVT (n=6) and stem (n=6) cell state from the TS cell *in vitro* model

was used with EVT and Stem labelled as phenotype 0 and 1, respectively.

Data visualization

Data from the scRNA-Seq assays were normalized and scaled with the NormalizeData

and ScaleData functions of Seurat[78]. Violin plots and feature plots were then generated using

default parameters.

Ethics Declaration

The study was approved by the Children's Mercy Institutional Review Board (Study No.

11120514). Informed written consent was obtained from the RPL participants before study

inclusion.

Human placental specimens

Sections of paraffin-embedded first trimester placenta tissue were obtained from the Lunenfeld-Tanenbaum Research Institute (Mount Sinai Hospital, Toronto, Canada) with written informed consent. Prior approval was granted by the respective local human research ethics review committees at the Mount Sinai Hospital and KUMC.

In situ hybridization

Transcripts for *TFAP2C, EPAS1, SNAI1, PLAC8*, and *CDH1* were localized within human first trimester placental tissue sections. RNAscope Multiplex Fluorescent Reagent Kit version 2 (Advanced Cell Diagnostics) was used for in situ hybridization analysis. Probes were prepared to detect *TFAP2C* (NM_003222.3, 515921, target region: 664-1596), *EPAS1* (NM_001430.4, 410591, target region: 1332-2354)*, SNAI1* (NM_005985.3, 560421, target region: 17-1233), *CDH1* (NM_004360.3, 311091-C2, target region: 263-1255), and *PLAC8* (NM_016619.3, 858491-C2, target region: 5-1448). *CDH1* and *PLAC8* probes were used to identify cytotrophoblast/trophoblast progenitor cells and differentiated EVT cells of the EVT cell column, respectively[47,48]. Fluorescence images were captured on a Nikon 90i upright microscope (Nikon) with a Photometrics CoolSNAP-ES monochrome camera (Roper).

shRNA-mediated gene silencing

Lentivirus-mediated shRNA delivery was used as a tool to test the biological roles for *TFAP2C*, *EPAS1*, and *SNAI1* in human TS cells. Several shRNAs designed for each target were subcloned into pLKO.1 and their efficacy tested by RT-qPCR and western blotting. An shRNA which does not recognize any known mammalian gene, pLKO.1-shSCR (Plasmid 1864) was used as a control (Addgene, Cambridge, MA). Sequences for shRNAs used in the analysis are provided in **Supplementary Table 20**. Construct design, lentivirus production, and lentiviral transduction were performed as previously described[20].

Transcript quantification by RT-qPCR

RNA was isolated with TRIzol/chloroform precipitation (15596018, Thermo-Fisher) as

previously described[20]. cDNA was synthesized from 1 μg of total RNA using the High-Capacity

cDNA Reverse Transcription Kit (Thermo-Fisher, 4368813) and diluted 10 times with ultra-pure

distilled water. qPCR was performed using PowerSYBR Green PCR Master Mix (4367659,

Thermo-Fisher) and primers (250 nM each). PCR primer sequences are listed in

Supplementary Table 21. Amplification and fluorescence detection were measured with a

QuantStudio 5 Flex Real-Time PCR System (Thermo-Fisher). An initial step (95°C, 10 min)

preceded 40 cycles of a two-step PCR (92°C, 15 s; 60°C, 1 min) and was followed by a

dissociation step (95°C, 15 s; 60°C, 15 s; 95°C 15 s). The comparative cycle threshold method

was used for relative quantification of the amount of mRNA for each sample normalized to

housekeeping genes *B2M* or *POLR2A*. Statistical analyses were performed using GraphPad

Prism 8 software. Welch's *t* tests, Brown-Forsythe and Welch ANOVA tests, or Two-way

ANOVA tests were applied when appropriate. Data is represented as mean ± standard deviation

with the statistical significance level set at *P*<0.05.

Western blotting

Western blotting was performed as previously described[20]. Briefly, cell lysates were

sonicated in radioimmunoprecipitation assay (**RIPA**) lysis buffer (sc-24948A, Santa Cruz

Biotechnology, Dallas, TX). Protein concentrations were measured with the DC Protein Assay

(5000112, Bio-Rad) and RIPA buffer was used as the blank standard. Proteins were separated

by SDS-PAGE and transferred onto polyvinylidene difluoride (**PVDF**) membranes (10600023,

GE Healthcare, Chicago, IL). Following the transfer, PVDF membranes were blocked with 5%

non-fat milk in Tris-buffered saline with 0.1% Tween 20 (**TBST**) and probed with primary

antibodies to SNAI1 (1:1000, 3879S, Cell Signaling Technology), EPAS1 (1:1000, 66731-1-Ig,

Proteintech), TFAP2C (1:750, 6E4/4, sc-12762, Santa Cruz Biotechnology), and glyeraldehyde-

3-phosphate dehydrogenase (**GAPDH**, 1:5000, AM4300, Thermo-Fisher) overnight at 4°C.

PVDF membranes were washed three times for 5 min each with TBST and incubated with

secondary antibodies (goat anti-rabbit IgG HRP, 1:5000, 7074S, Cell Signaling Technology and

horse anti-mouse IgG HRP, 7076, Cell Signaling Technology) for 1 h at room temperature.

Immunoreactive proteins were visualized using the Luminata^{TM} Crescendo Western HRP

Substrate (WBLUR0500, Millipore, Billerica, MA) according to the manufacturer's instructions.

RNA-seq analysis for silencing experiment

Stranded mRNA-Seq was performed using the Illumina NovaSeq 6000 Sequencing

System at the University of Kansas Medical Center – Genomics Core (Kansas City, KS). Quality

control was completed using the Agilent TapeStation 4200 with the RNA ScreenTape Assay kit

(Agilent Technologies 5067-5576). Total RNA (1 µg) was used to initiate the library preparation

protocol. The total RNA fraction was processed by oligo dT bead capture of mRNA,

fragmentation, reverse transcription into cDNA, end repair of cDNA, ligation with the appropriate

Unique Dual Index (UDI) adaptors, strand selection, and library amplification by PCR using the

Universal Plus mRNA-Seq with NuQuant library preparation kit (0520-A01, Tecan Genomics).

Library validation was performed using the D1000 ScreenTape Assay kit (5067-5582, Agilent)

on the Agilent TapeStation 4200. The concentration of each library was determined with the

NuQuant module of the library prep kit using a Qubit 4 Fluorometer (Thermo-Fisher/Invitrogen).

Libraries were pooled based on equal molar amounts and the multiplexed pool was quantified,

in triplicate, using the Roche Lightcycler96 with FastStart Essential DNA Green Master

(06402712001, Roche 0) and KAPA Library Quant (Illumina) DNA Standards 1-6 (KK4903,

KAPA Biosystems). Using the qPCR results, the RNA-Seq library pool was adjusted to 2.125

nM for multiplexed sequencing. Pooled libraries were denatured with 0.2 N NaOH (0.04N final

concentration) and neutralized with 400 mM Tris-HCl, pH 8.0. A dilution of the pooled libraries to

425 pM was performed in the sample tube on the instrument and followed by onboard clonal

clustering of the patterned flow cell using the NovaSeq 6000 S1 Reagent Kit (200 cycle)

(20012864, Illumina). A 2x101 cycle sequencing profile with dual index reads was completed

using the following sequence profile: Read 1 – 101 cycles x Index Read 1 – 8 cycles x Index

Read 2 – 8 cycles x Read 2 – 101 cycles. Following collection, sequence data were converted

from .bcl file format to fastq file format using bcl2fastq software and de-multiplexed into

individual sequences and downstream analysis performed as described above.

GWAS data analysis and integration

Summary statistics from UK Biobank GWAS was accessed at http://www.nealelab.is/uk-

biobank. Odds ratio of the proportion of nominally significant (P<0.05) hits in the *EPAS1* gene

region (GRCh38; chr2:46,150,000-46,450,000) was computed and compared with variants in a

randomly selected matched window. This step was repeated 1000 times for each phenotype to

generate a distribution of odds ratio. To compute significance using Wilcoxon test, a null

distribution was generated to compare against. For each permutation, another randomly

selected matched window size was selected and compared with the first randomly selected

region chosen in step 1.

DATA AVAILABILITY

Raw and processed sequencing data from ATAC-Seq, RNA-Seq and Hi-C have been

submitted to the NCBI Gene Expression Omnibus (GEO). Processed data can be visualized in

the UCSC Genome Browser. The ChIP-seq data of histone modifications are deposited in

Japanese Genotype-phenotype Archive (JGA).

CODE AVAILABILITY

Only publicly available tools were used in data analysis as described wherever relevant in the Methods.

REFERENCES

1. Brosens, I., Puttemans, P. & Benagiano, G. Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes. *Am. J. Obstet. Gynecol.* **221**, 437–456 (2019).

2. Velicky, P., Knöfler, M. & Pollheimer, J. Function and control of human invasive trophoblast subtypes: Intrinsic vs. maternal control. *Cell Adhes. Migr.* **10**, 154–162 (2016).

3. Knöfler, M. *et al.* Human placenta and trophoblast development: key molecular mechanisms and model systems. *Cell. Mol. Life Sci. CMLS* **76**, 3479–3496 (2019).

4. Damsky, C. H. & Fisher, S. J. Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. *Curr. Opin. Cell Biol.* **10**, 660–666 (1998).

5. Burton, G. J., Woods, A. W., Jauniaux, E. & Kingdom, J. C. P. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. *Placenta* **30**, 473–482 (2009).

6. Kidder, B. L. & Palmer, S. Examination of transcriptional networks reveals an important role for TCFAP2C, SMARCA4, and EOMES in trophoblast stem cell maintenance. *Genome Res.* **20**, 458–472 (2010).

7. Rugg-Gunn, P. J., Cox, B. J., Ralston, A. & Rossant, J. Distinct histone modifications in stem cell lines and tissue lineages from the early mouse embryo. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 10783–10790 (2010).

8. Chuong, E. B., Rumi, M. A. K., Soares, M. J. & Baker, J. C. Endogenous retroviruses function as species-specific enhancer elements in the placenta. *Nat. Genet.* **45**, 325–329 (2013).

9. Latos, P. A. *et al.* Elf5-centered transcription factor hub controls trophoblast stem cell self-renewal and differentiation through stoichiometry-sensitive shifts in target gene networks. *Genes Dev.* **29**, 2435–2448 (2015).

10. Latos, P. A. *et al.* Fgf and Esrrb integrate epigenetic and transcriptional networks that regulate self-renewal of trophoblast stem cells. *Nat. Commun.* **6**, 7776 (2015).

11. Rhee, C. *et al.* Mechanisms of transcription factor-mediated direct reprogramming of mouse embryonic stem cells to trophoblast stem-like cells. *Nucleic Acids Res.* **45**, 10103–10114 (2017).

12. Lee, B.-K. *et al.* Super-enhancer-guided mapping of regulatory networks controlling mouse trophoblast stem cells. *Nat. Commun.* **10**, 4749 (2019).

13. Schoenfelder, S. *et al.* Divergent wiring of repressive and active chromatin interactions between mouse embryonic and trophoblast lineages. *Nat. Commun.* **9**, 4189 (2018).

14. Todd, C. D., Deniz, Ö., Taylor, D. & Branco, M. R. Functional evaluation of transposable elements as enhancers in mouse embryonic and trophoblast stem cells. *eLife* **8**, (2019).

15. Benchetrit, H. *et al.* Extensive nuclear reprogramming underlies lineage conversion into functional trophoblast stem-like cells. *Cell Stem Cell* **17**, 543–556 (2015).

16. Kubaczka, C. *et al.* Direct induction of trophoblast stem cells from murine fibroblasts. *Cell Stem Cell* **17**, 557–568 (2015).

17. Abell, A. N. *et al.* MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. *Cell Stem Cell* **8**, 525–537 (2011).

18. Tuteja, G., Chung, T. & Bejerano, G. Changes in the enhancer landscape during early placental development uncover a trophoblast invasion gene-enhancer network. *Placenta* **37**, 45–55 (2016).

19. Kubota, K., Kent, L. N., Rumi, M. A. K., Roby, K. F. & Soares, M. J. Dynamic regulation of AP-1 transcriptional complexes directs trophoblast differentiation. *Mol. Cell. Biol.* **35**, 3163–3177 (2015).

20. Varberg, K. M. *et al.* ASCL2 reciprocally controls key trophoblast lineage decisions during hemochorial placenta development. *Proc. Natl. Acad. Sci. U. S. A.* **118**, (2021).

21. Lee, C. Q. E. *et al.* What is trophoblast? A combination of criteria define human first-trimester trophoblast. *Stem Cell Rep.* **6**, 257–272 (2016).

22. Okae, H. *et al.* Derivation of human trophoblast stem cells. *Cell Stem Cell* **22**, 50-63.e6 (2018).

23. Takahashi, S. *et al.* Loss of p57KIP2 expression confers resistance to contact inhibition in human androgenetic trophoblast stem cells. *Proc. Natl. Acad. Sci. U. S. A.* (2019) doi:10.1073/pnas.1916019116.

24. Saha, B. *et al.* TEAD4 ensures postimplantation development by promoting trophoblast self-renewal: An implication in early human pregnancy loss. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 17864–17875 (2020).

25. Perez-Garcia, V. *et al.* Placentation defects are highly prevalent in embryonic lethal mouse mutants. *Nature* **555**, 463–468 (2018).

26. Muto, M. *et al.* Intersection of regulatory pathways controlling hemostasis and hemochorial placentation. *Proc. Natl. Acad. Sci. U. S. A.* **118**, e2111267118 (2021).

27. Suryawanshi, H. *et al.* A single-cell survey of the human first-trimester placenta and decidua. *Sci. Adv.* **4**, eaau4788 (2018).

28. Vento-Tormo, R. *et al.* Single-cell reconstruction of the early maternal-fetal interface in humans. *Nature* **563**, 347–353 (2018).

29. Meuleman, W. *et al.* Index and biological spectrum of human DNase I hypersensitive sites. *Nature* **584**, 244–251 (2020).

30. Roadmap Epigenomics Consortium *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317–330 (2015).

31. Bernstein, B. E. *et al.* A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell* **125**, 315–326 (2006).

32. Pott, S. & Lieb, J. D. What are super-enhancers? *Nat. Genet.* **47**, 8–12 (2015).

33. Moorthy, S. D. *et al.* Enhancers and super-enhancers have an equivalent regulatory role in embryonic stem cells through regulation of single or multiple genes. *Genome Res.* **27**, 246–258 (2017).

34. Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934–947 (2013).

35. Rao, S. S. P. *et al.* A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* **159**, 1665–1680 (2014).

36. Greenwald, W. W. *et al.* Subtle changes in chromatin loop contact propensity are associated with differential gene regulation and expression. *Nat. Commun.* **10**, 1054 (2019).

37. Guelen, L. *et al.* Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. *Nature* **453**, 948–951 (2008).

38. Kubo, N. *et al.* Promoter-proximal CTCF binding promotes distal enhancer-dependent gene activation. *Nat. Struct. Mol. Biol.* **28**, 152–161 (2021).

39. Durand, N. C. *et al.* Juicer Provides a One-Click System for Analyzing Loop-Resolution Hi-C Experiments. *Cell Syst.* **3**, 95–98 (2016).

40. Morey, R. *et al.* Transcriptomic drivers of differentiation, maturation, and polyploidy in human extravillous trophoblast. *Front. Cell Dev. Biol.* **9**, 702046 (2021).

41. Liu, Y. *et al.* Single-cell RNA-seq reveals the diversity of trophoblast subtypes and patterns of differentiation in the human placenta. *Cell Res.* **28**, 819–832 (2018).

42. Meinhardt, G. *et al.* Wnt-dependent T-cell factor-4 controls human extravillous trophoblast motility. *Endocrinology* **155**, 1908–1920 (2014).

43. Dong, C. *et al.* A genome-wide CRISPR-Cas9 knockout screen identifies essential and growth-restricting genes in human trophoblast stem cells. *Nat. Commun.* **13**, 2548 (2022).

44. Meinhardt, G. *et al.* Pivotal role of the transcriptional co-activator YAP in trophoblast stemness of the developing human placenta. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 13562–13570 (2020).

45. Krendl, C. *et al.* GATA2/3-TFAP2A/C transcription factor network couples human pluripotent stem cell differentiation to trophectoderm with repression of pluripotency. *Proc. Natl. Acad. Sci. U. S. A.* **114**, E9579–E9588 (2017).

46. Liu, X. *et al.* Reprogramming roadmap reveals route to human induced trophoblast stem cells. *Nature* **586**, 101–107 (2020).

47. Renaud, S. J. *et al.* OVO-like 1 regulates progenitor cell fate in human trophoblast development. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E6175-6184 (2015).

48. Chang, W.-L. *et al.* PLAC8, a new marker for human interstitial extravillous trophoblast cells, promotes their invasion and migration. *Dev. Camb. Engl.* **145**, dev148932 (2018).

49. West, R. C. *et al.* Dynamics of trophoblast differentiation in peri-implantation-stage human embryos. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 22635–22644 (2019).

50. Sheng, W. *et al.* LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. *Cell* **174**, 549-563.e19 (2018).

51. Jeyarajah, M. J. *et al.* The multifaceted role of GCM1 during trophoblast differentiation in the human placenta. *Proc. Natl. Acad. Sci. U. S. A.* **119**, e2203071119 (2022).

52. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. *Nat. Rev. Mol. Cell Biol.* **3**, 155–166 (2002).

53. Vasconcelos, S., Ramalho, C., Marques, C. J. & Doria, S. Altered expression of epigenetic regulators and imprinted genes in human placenta and fetal tissues from second trimester spontaneous pregnancy losses. *Epigenetics* **14**, 1234–1244 (2019).

54. Sasagawa, T. *et al.* HIF-2α, but not HIF-1α, mediates hypoxia-induced up-regulation of Flt-1 gene expression in placental trophoblasts. *Sci. Rep.* **8**, 17375 (2018).

55. Soares, M. J., Chakraborty, D., Kubota, K., Renaud, S. J. & Rumi, M. A. K. Adaptive mechanisms controlling uterine spiral artery remodeling during the establishment of pregnancy. *Int. J. Dev. Biol.* **58**, 247–259 (2014).

56. Warrington, N. M. *et al.* Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. *Nat. Genet.* **51**, 804–814 (2019).

57. Pijnenborg, R., Vercruysse, L. & Hanssens, M. The uterine spiral arteries in human pregnancy: facts and controversies. *Placenta* **27**, 939–958 (2006).

58. Xie, W. *et al.* Epigenomic analysis of multilineage differentiation of human embryonic stem cells. *Cell* **153**, 1134–1148 (2013).

59. Dixon, J. R. *et al.* Chromatin architecture reorganization during stem cell differentiation. *Nature* **518**, 331–336 (2015).

60. Zhu, M. *et al.* Developmental clock and mechanism of de novo polarization of the mouse embryo. *Science* **370**, eabd2703 (2020).

61. E Davies, J. *et al.* Epithelial-mesenchymal transition during extravillous trophoblast differentiation. *Cell Adhes. Migr.* **10**, 310–321 (2016).

62. Fryer, B. H. & Simon, M. C. Hypoxia, HIF and the placenta. *Cell Cycle Georget. Tex* **5**, 495–498 (2006).

63. Rajakumar, A. & Conrad, K. P. Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta. *Biol. Reprod.* **63**, 559–569 (2000).

64. Fujii, T. *et al.* Enhanced HIF2α expression during human trophoblast differentiation into syncytiotrophoblast suppresses transcription of placental growth factor. *Sci. Rep.* **7**, 12455 (2017).

65. Loboda, A., Jozkowicz, A. & Dulak, J. HIF-1 and HIF-2 transcription factors--similar but not identical. *Mol. Cells* **29**, 435–442 (2010).

66. Pugh, C. W. Modulation of the hypoxic response. *Adv. Exp. Med. Biol.* **903**, 259–271 (2016).

67. Johnson, E. A. HIF takes it up a notch. *Sci. Signal.* **4**, pe33 (2011).

68. Rajakumar, A. *et al.* Selective overexpression of the hypoxia-inducible transcription factor, HIF-2alpha, in placentas from women with preeclampsia. *Biol. Reprod.* **64**, 499–506 (2001).

69. Dong, C. *et al.* Derivation of trophoblast stem cells from naïve human pluripotent stem cells. *eLife* **9**, e52504 (2020).

70. Cinkornpumin, J. K. *et al.* Naive human embryonic stem cells can give rise to cells with a trophoblast-like transcriptome and methylome. *Stem Cell Rep.* **15**, 198–213 (2020).

71. Corces, M. R. *et al.* An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. *Nat. Methods* **14**, 959–962 (2017).

72. Amemiya, H. M., Kundaje, A. & Boyle, A. P. The ENCODE Blacklist: Identification of Problematic Regions of the Genome. *Sci. Rep.* **9**, 9354 (2019).

73. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinforma. Oxf. Engl.* **26**, 841–842 (2010).

74. Wolff, J. *et al.* Galaxy HiCExplorer 3: a web server for reproducible Hi-C, capture Hi-C and single-cell Hi-C data analysis, quality control and visualization. *Nucleic Acids Res.* **48**, W177–W184 (2020).

75. Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589 (2010).

76. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Definitions of infertility and recurrent pregnancy loss: a committee opinion. *Fertil. Steril.* **113**, 533–535 (2020).

77. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 200: Early Pregnancy Loss. *Obstet. Gynecol.* **132**, e197–e207 (2018).

78. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587.e29 (2021).

79. Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol.* **20**, 296 (2019).

80. Ahlmann-Eltze, C. & Huber, W. glmGamPoi: fitting Gamma-Poisson generalized linear models on single cell count data. *Bioinforma. Oxf. Engl.* **36**, 5701–5702 (2021).

81. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).

82. Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. *Bioinforma. Oxf. Engl.* **35**, 2084–2092 (2019).

83. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550 (2005).

84. Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003).

ACKNOWLEDGEMENTS

We thank Stacy Oxley, Brandi Miller, and Nhu Bui for their administrative assistance, Dan Louiselle, and Rebecca Biswell for their work in sample processing, Adam Walters and Margaret Gibson for their work in library preparation and NGS and Bradley Belden and Mackenzie Stevens for their work in clinical coordination. The research was supported by an NRSA postdoctoral fellowship to K.M.V. from the National Institutes of Health (F32HD096809), grants from the National Institutes of Health (HD020676, HD079363, HD099638, HD105734, GM146966, HG012422), the Sosland Foundation, KAKENHI Grant Number 19H05757, and AMED Grant Number JP22gm1310001. E.G holds the Roberta D. Harding & William F. Bradley, Jr. Endowed Chair in Genomic Research.

AUTHOR CONTRIBUTIONS

K.M.V., H.O., T.A., M.J.S., and E.G. conceived and designed the research; K.M.V.,

E.M.D, A.M., R.M, and H.O. performed experiments; H.O., T.A., M.L., K.H., and C.M. provided

reagents. K.M.V, E.M.D., B.K., J.M.V., A.M., E.W., R.P.M., K.I., W.C., C.S-S., C.S., M.J.S., and

E.G. analyzed the data and interpreted results of experiments; K.M.V., B.K., C. S-S., M.J.S.,

and E.G. prepared figures and drafted manuscript; K.M.V., M.J.S., and E.G. edited and revised

manuscript; All authors approved the final version of manuscript.

COMPETING INTEREST STATEMENT

The authors declare no competing interest.

1   **FIGURES**

3   **Figure 1. Morphologic and transcriptomic changes during EVT cell differentiation from**

4   **human trophoblast stem (TS) cells. a)** Simplified schematic depicting the three primary

analyses (RNA-Seq, ATAC-Seq, and Hi-C) performed on human TS cell models in the stem

state and following eight days of extravillous trophoblast (**EVT**) cell differentiation. **b)** Principal

component analysis (PCA) plot depicting Stem (red), EVT Day 3 (green), EVT Day 6 (light blue),

and EVT Day 8 (dark blue) cell data of normalized read counts from RNA-Seq datasets. **c)** Log$_2$

fold-change values of normalized read counts from RNA-Seq of key EVT cell-specific transcripts

(*ASCL2*, *HLA-G*, *ITGA1*, and *MMP2*) at stem state and on day 3, 6, and 8 of EVT cell

differentiation compared to the stem state. **d)** Mean *HLA-G* expression/cell (top) and the

percentage of HLA-G positive cells detected by flow cytometry in CT27 (left) and CT29 (right)

cells in the stem state and on days 3, 6, and 8 of EVT cell differentiation (n=3-5 replicates per

group; ****p<0.0001). Graphs depict mean ± standard deviation (**SD**). **e)** Phase contrast images

of TS cells cultured in the stem state and on days 3, 6, and 8 of EVT cell differentiation in CT27

and CT29 cell lines. Stem state cells maintain a cobble-stone morphology and proliferate to

form discrete cell colonies. EVT cell differentiation is accompanied by cell elongation. Scale

bars represent 500 μm. **f)** Volcano plot depicting transcriptomic changes in EVT cells (CT27 and

CT29) on day 8 of differentiation compared to stem state cells (CT27 and CT29) measured by

RNA-Seq. Differentially expressed transcripts (absolute log2 fold change >1, adjusted p value

<0.05) are labeled in red. Key stem state (*ELF5, EPCAM, F3, LIN28A, LRP2, and TEAD4*) and

EVT cell (*ASCL2, FSTL3, HLA-G, ITGA1, ITGA5, MMP2,* and *NOTUM*) transcripts are

annotated.

Figure 2. Validation of *in vitro* signatures of the TS model in single cell datasets from human placental samples. a) UMAP plot depicting cell clustering from two publicly available, independent, single-cell RNA sequencing (**scRNA-Seq**) datasets from first-trimester placentas[27,28]. Cell types are inferred using marker genes published previously[28] as decidual macrophages (**dM**), fetal (**Endo f**) and maternal endothelial cells (**Endo m**), epithelial glandular cells (**Epi**), extravillous trophoblast cells (**EVT**), fetal fibroblasts (**FB**), Hofbauer cells (**HB**), syncytiotrophoblast and villous cytotrophoblast (**SCT/VCT**) and cells not determined (**ND**). **b)** UMAP plots showing expression levels of EVT cell-specific genes detected in *in vitro* model. **c-e)** Plots depicting gene set enrichment analysis using three genes sets (each N=250) of genes significantly upregulated in **c**) SCT/VCT cells or **(d)**, EVT cells or **(e)** genes not differently expressed between SCT/VCT and EVT cells from scRNA-Seq data sets and tested for

enrichment for expression pattern in stem state (phenotype 1, CT27) and EVT cells (phenotype

0, CT27) from the *in vitro* TS model. Enrichment score (**ES**) reflects the degree of which each

gene set is overrepresented at the extremes (top or bottom) of genes expressed in phenotype 0

(EVT cells) versus phenotype 1 (stem state cells). Estimated significance of ES were accounted

for multiple testing and corresponded to **b**) Phenotype 0; FDR q value=NS; Phenotype 1; FDR q

value=0.00190 **c**) Phenotype 0; FDR q value=0.00196; Phenotype 1; FDR q value=NS and **d**)

Phenotype 0; FDR q value=NS; Phenotype 1; FDR q value=0.0016. FDR=false discovery rate;

NS=not significant.

Figure 3. EVT cell differentiation drives global changes in chromatin accessibility. a) bar

graphs depicting the fraction of chromatin accessible regions across five defined genomic

regions (e.g., transcription termination site (**TTS**), promoter-transcription start site (**TSS**), intron,

intergenic, and exon regions). Chromatin accessible regions were identified by ATAC-Seq and

are classified into three primary groups: regions that are 1) unique to stem state cells, 2) shared

between stem and EVT cells or 3) unique to EVT cells. **b)** Tornado plots showing the density of

chromatin accessible regions within 10 kb of TSS that are unique to EVT cells, unique to stem

state cells, or shared between the two cell states. Colorimetric scale (red to blue) represents

coverage intensity. **c)** Tornado plots showing ATAC-Seq coverage in peak regions from ChIP-

Seq of H3K4me3 and H3K27ac in EVT and stem state cells, respectively. Colorimetric scale

(red to blue) represents coverage intensity **(d, e)** bar graphs depicting the fraction of

differentially enriched chromatin accessible regions identified by ATAC-Seq in stem state **(d)** or

EVT **(e)** cells across three chromatin states defined by histone modifications: H3K4me3

(putative poised promoters), H3K27ac (active enhancers) and H3K4me3+H3K27ac (active

promoters). **f)** Schematic depicting regulatory regions selected for transcription factor (**TF**)

analysis and motifs for three top TFs identified in the analysis,

Figure 4. Long-range chromatin interactions in stem state and EVT cells. a) Hi-C contact

maps at 5kb resolution across all chromosomes in stem state and EVT cells. **b, c)** Hi-C contact

maps zoomed in to 5kb resolution on **b)** chromosome 7 and **c)** *DLX6* locus for stem state and

EVT cells. Identified loops are marked as black (all) or blue (cell-specific) boxes on either side of

the map. RefSeq genes (green track) and ATAC-Seq (blue tracks, counts per million mapped

reads, y-axis) are used for annotation. Yellow box indicates a EVT cell-specific loop at

chromatin accessible regions specific to EVT at the *DLX6* locus. **d)** Aggregate plot depicting

EVT chromatin loop interactions at 9,334 EVT cell differentially accessed chromatin regions

centered between total number of bins used in the submatrix (N=20). Enrichment is calculated

based on transformation of observed to expected interactions and shown from low (0.8) to high

(2.2) enrichment as illustrated using blue to red color scale. **e)** Hi-C, RNA-Seq, ATAC-Seq, and

H3K4me3 and H3K27ac ChIP-Seq assessments performed in CT27 cells differentiated into

EVT cells (top panel) or maintained in the stem state (bottom panel). Regulatory elements near

DLX5/DLX6 are shown and include Hi-C loops (red, both loop anchors in view; blue, loop

anchors out of view), RNA-Seq (transcripts per million, y-axis), ATAC-Seq (counts per million

mapped reads, y-axis), H3K4me3, and H3K27ac ChIP-Seq (counts per million mapped reads,

y-axis). All datasets are shown in individual tracks. Super-enhancers (SE, red) and differentially

bound regions (**DB**, blue) are specific to the EVT cell state. Key regulatory regions are

highlighted in yellow.

Figure 5. Expression of transcription factors in single EVT cells derived from human

placenta. Data from two publicly available, independent, single-cell RNA sequencing (scRNA-

Seq) datasets from first trimester placentas[27,28] is used and cell types are inferred using marker

genes published previously[28] as decidual macrophages (**dM**), fetal (**Endo f**) and maternal

endothelial cells (**Endo m**), epithelial glandular cells (**Epi**), extravillous trophoblast cells (**EVT**),

fetal fibroblasts (**FB**), Hofbauer cells (**HB**), syncytiotrophoblast and villous cytotrophoblast

(**SCT/VCT**) and cells not determined (**ND**). Single cell expression values for five transcription

factors (*ASCL2*; *DLX6*; *EPAS1*, *MYCN* and *SNAI1*) shown in **a)** Violin plots comparing EVT cells

(orange) with syncytiotrophoblast (**SCT**) and villous cytotrophoblast cells (**VCT**) combined

(turquoise) and **b)** UMAP feature plots.

2 **Figure 6. Functional assessment of *TFAP2C* actions in trophoblast cell development.**

3 **a)** Representative human placental tissue specimen (12 weeks of gestation) probed for

4 *TFAP2C*, *CDH1*, and *PLAC8* transcripts using *in situ* hybridization. DAPI labels cell nuclei.

5 Overlay of merged immunofluorescence images: *TFAP2C* (red), DAPI (gray), and either *CDH1*

(green) or *PLAC8* (green), respectively. Scale bars represent 50 µm (*CDH1* image panels) and

100 µm (*PLAC8* image panels). **b)** RT-qPCR measurement of *TFAP2C* normalized to *POLR2A*

in stem and EVT cells (ns=not significant p>0.05; n=4 per group). **c)** TFAP2C (50 kDa) and

GAPDH (37 kDa) proteins in stem and EVT cells assessed by western blot analysis. **d)** Log_2

fold-change values of normalized read counts of *TFAP2C* from RNA-Seq in stem state and days

3, 6, and 8 of EVT cell differentiation compared to the Stem state. **e)** RT-qPCR measurement of

TFAP2C normalized to *POLR2A* in stem state cells transduced with lentivirus containing a

control shRNA (**shC**) or a *TFAP2C*-specific shRNA (**shTFAP2C**; n=4 per group; **p<0.01). **f)**

TFAP2C (50 kDa) and GAPDH (37 kDa) proteins in stem state cells transduced with shC or

shTFAP2C and assessed by western blot. **g)** Phase contrast images of stem state cells

transduced with shC or shTFAP2C. Scale bar represents 250 µm. **h)** Heat map based on

scaled, normalized counts of selected differentially expressed transcripts generated from RNA-

Seq in shC (control, **Ctrl**; orange) or shTFAP2C (knockdown, **KD**; blue) transduced cells.

Transcripts are clustered into four groups including cell cycle (purple), EVT-specific (pink), stem

state-specific (green), or other (blue). *Depict genes identified as direct targets of TFAP2C

based on ChIP-Seq analysis in TS cells. Graphs in panels B and E depict mean ± standard

deviation.

Figure 7. Expression patterns of *SNAI1*, and *EPAS1*. a) Human placental tissue specimen

(12 weeks of gestation) probed for *SNAI1, EPAS1, CDH1* and *PLAC8* transcripts using *in situ*

hybridization. DAPI labels cell nuclei. Overlay of merged immunofluorescence images: *SNAI1*

(red), or *EPAS1* (red), with DAPI (gray), and *CDH1* (green) or *PLAC8* (green). Scale bars

represent 100 μm in *CDH1* image panels and 50 μm in *PLAC8* image panels. **b)** Log$_2$ fold-

change values of normalized read counts of *SNAI1 and EPAS1* from RNA-Seq in stem state

and days 3, 6, and 8 of EVT cell differentiation compared to the Stem state. **c)** RT-qPCR

measure of *SNAI1* (Stem n=6; EVT n=4), and *EPAS1* (n=6 per group) normalized to *B2M* in

stem and EVT cells (*p<0.05 and ****p<0.0001). Graphs depict mean ± standard deviation (SD).

d) SNAI1 (29 kDa), EPAS1 (120 kDa), and GAPDH (37 kDa) protein in stem and EVT cells

assessed by western blot analysis.

Figure 8. Functional investigation of *SNAI1* on EVT cell differentiation in CT27 cells. a)

RT-qPCR measurement of *SNAI1* (n=5 per group) normalized to *B2M* in EVT cells differentiated

from stem state cells transduced with lentivirus containing a control shRNA (**shC**) or SNAI1-

specific shRNA (**shSNAI1**). Graph depicts mean ± standard deviation. **b)** SNAI1 (29 kDa) and

GAPDH (37 kDa) protein in EVT cells from shC control or shSNAI1 treated cells measured by

western blot. **c)** Phase contrast images of shC control or shSNAI1 EVT cells following eight

days of differentiation. Scale bars represent 500 μm. **d)** Heat map based on scaled, normalized

counts of selected transcripts generated from RNA-Seq in shC (control, **Ctrl**; orange) or

shSNAI1 (knockdown, **KD**; blue) transduced cells (n=3 per group). Transcripts are clustered into

three groups including EVT-specific (pink), EVT interferon (**IFN**) responsive (purple), or stem

state-specific (green). **e)** Hi-C, RNA-Seq, ATAC-Seq, and H3K4me3 and H3K27ac ChIP-Seq

assessments performed in CT27 cells differentiated into EVT cells (top panel) or maintained in

the stem state (bottom panel). Identified regulatory elements near *SNAI1* are highlighted in

orange and overlap Hi-C loops (red, both loop anchors in view; blue, loop anchors out of view),

open chromatin by ATAC-Seq (counts per million mapped reads, y-axis), and promoter or

enhancer mark by H3K4me3, or H3K27ac ChIP-Seq, respectively (counts per million mapped

reads, y-axis). Expression level is shown by RNA-Seq (transcripts per million, y-axis). All

datasets are shown in individual tracks. Super-enhancers (**SE**, red) and differentially bound

regions (**DB**, blue) are specific to the EVT cell state.

Figure 9. Functional investigation of *EPAS1* on EVT cell differentiation in CT27 cells. a)

RT-qPCR measurement of *EPAS1* (n=3 per group) normalized to *B2M* in EVT cells

differentiated from stem state cells transduced with lentivirus containing a control shRNA (**shC**) or a EPAS1-specific shRNA (**shEPAS1**). Graph depicts mean ± standard deviation. **b)** EPAS1 (120 kDa) and GAPDH (37 kDa) protein in EVT cells from shC control or shEPAS1 treated cells measured by western blot. **c)** Phase contrast images of shC control or shEPAS1 EVT cells following eight days of differentiation. Scale bars represent 500 μm. **d)** Heat map based on scaled, normalized counts of selected transcripts generated from RNA-Seq in shC control (**Ctrl**, orange) or shEPAS1 (**KD**, blue) transduced cells (n=3 per group). Transcripts are clustered into two groups including EVT-specific (pink) or stem state-specific (green). **e)** Hi-C, RNA-Seq, ATAC-Seq, and H3K4me3 and H3K27ac ChIP-Seq assessments performed in CT27 cells differentiated into EVT cells (top panel) or maintained in the stem state (bottom panel). Identified regulatory elements near *EPAS1* are highlighted in orange and overlap Hi-C loops (red, both loop anchors in view; blue, loop anchors out of view), open chromatin by ATAC-Seq (counts per million mapped reads, y-axis), and promoter or enhancer mark by H3K4me3, or H3K27ac ChIP-Seq, respectively (counts per million mapped reads, y-axis). Expression level is shown by RNA-Seq (transcripts per million, y-axis). All datasets are shown in individual tracks. Super-enhancers (**SE**, red) and differentially bound regions (**DB**, blue) are specific to the EVT cell state. SNPs associated with pregnancy loss (PL) or birth weight (BW) in large genome-wide association studies (GWAS) are shown in brown circles. **f)** Violin plot of *EPAS1* expression in EVT cells generated from single-cell RNA-Seq analysis of human first trimester placental samples derived from control patients (**Control**, orange) and patients experiencing recurrent pregnancy loss (**RPL**, turquoise). The y-axis represents normalized and natural log transformed *EPAS1* expression levels. **g)** Schematic of transcriptional regulatory hierarchy controlling extravillous trophoblast (**EVT**) cell differentiation. *TFAP2C* is important for maintenance of human TS cells in the stem state and transition to the differentiation state. *EPAS1* is induced upon EVT cell differentiation and acts as an upstream regulator of several EVT cell-specific transcription factors, including *ASCL2*, *SNAI1*, *DLX6*, and *MYCN*.